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ABSTRACT  
 
The placenta provides the interface between the fetal and maternal 
environments, exchanging gases, nutrients and waste products between the 
mother and the growing fetus, serving as an endocrine organ by producing 
several pregnancy-associated hormones and growth factors and protecting 
the fetus from maternal immune attack. Placentation – placenta formation and 
development - is a continuous and highly regulated process that initiates 
immediately upon fertilization and ends only after delivery. Extravillous 
trophoblasts (EVTs) are the key cells involved in the placentation process. 
They are fully specialized trophoblasts displaying an invasive and proliferative 
phenotype, which perform the anchorage of the chorionic villi into the uterine 
wall and actively regulate uterine spiral arteries remodeling, a process that 
ends up with the establishment of the utero-placental blood flow. 
The major aim of this study was to investigate the impact of 
xenobiotics upon placental transport of important nutrients (glucose (GLU), 
the long-chain polyunsaturated fatty acids (LC-PUFAs) arachidonic (ARA) and 
docohexaenoic (DHA) acids, folic acid (FA) and the amino acid L-methionine 
(L-Met)), and its implication on the process of placentation, using human first 
trimester human EVTs (HTR-8/SVneo cell line). Moreover, we intended to 
develop an experimental cellular model of EVTs insufficiency and to revert 
this insufficiency, by improving the nutritional status of the cells. 
Our results led us to conclude that in the HTR-8/SVneo cell line: a) GLU 
uptake seem to be mediated by the facilitative glucose transporter 1 (GLUT1), 
ARA uptake seem to be mediated by long-chain acyl-CoA synthetase 1 (ACSL1) 
and FA uptake seem to be mediated by proton-coupled folate transporter 
(PCFT); b) long-term (24h) exposure to xanthohumol (XN) interferes with 
placentation-related processes, as it decreases cell viability, culture growth, 
- 26 - 
 
proliferation, migration and increases apoptosis rates; c) the inhibitory effect 
of XN upon placentation-related processes is dependent on the cellular levels 
of GLU and ARA, as XN inhibits the cellular uptake of these nutrients and its 
effects on placentation-related processes were reverted by increasing the 
extracellular levels of either GLU or ARA; and d) ethanol (EtOH) and 
metformin (METF) inhibit GLU and FA cellular uptake, and interfere with 
placentation-related processes. In relation to the mechanism of action of these 
xenobiotics, the following intracellular signaling pathways were found to be 
implicated in the observed effects: a) the mammalian target of rapamycin 
(mTOR), c-Jun-N-terminal kinase (JNK) and tyrosine kinases (TK) appear to 
mediate the effect of XN upon ARA and GLU uptake; b) mTOR, JNK and 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) appear to be involved 
in the effect of EtOH upon FA uptake and in the effect of METF upon cell 
viability; and c) mTOR and JNK appear to be involved in the effect of EtOH 
upon cell viability and GLU uptake. 
 In conclusion, exposure to different xenobiotics during pregnancy may 
affect the transport of essential nutrients to the placenta, and this may have a 
deleterious effect upon the placentation process, with detrimental 
consequences to fetal growth and development. 
 
 
 
 
 
Keywords: apoptosis; arachidonic acid; extravillous trophoblast cells; folic 
acid; glucose; placenta; placentation; cell proliferation; cell migration; nutrient 
uptake; transmembrane transport; xanthohumol; xenobiotics. 
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RESUMO  
 
A placenta humana constitui a principal ligação entre a mãe e o feto, 
sendo responsável pela troca materno-fetal de gases e nutrientes. Serve ainda 
de órgão endócrino, sendo responsável pela produção de hormonas 
associadas a gravidez, bem como de factores de crescimento e proteção do 
feto em desenvolvimento relativamente a resposta imunitária materna. A 
placentação – formação e desenvolvimento da placenta – é um processo 
contínuo e altamente regulado que se inicia imediatamente após fertilização e 
termina apenas aquando do parto. As células trofoblásticas extravilositárias 
(TEV) são células chave envolvidas no processo de placentação. Estas são 
células trofoblásticas com fenótipo invasivo e proliferativo; realizam a 
ancoragem das árvores vilositárias na cavidade intrauterina e regulam 
ativamente a remodelação das artérias espirais maternas, processo este que 
termina aquando do estabelecimento do fluxo sanguíneo utero-placentário. 
O nosso principal objetivo foi investigar o impacto de xenobióticos no 
transporte materno-fetal de nutrientes essenciais ao crescimento e 
desenvolvimento placentário e fetal, mais especificamente a glicose (GLI), os 
ácidos gordos polinsaturados de cadeia longa ácido (araquidónico [AA] e ácido 
docosahexaenóico [ADH]), o ácido fólico (AF) e o aminoácido L-metionina (L-
Met), bem como as suas implicações no processo de placentação. Para tal, 
recorremos a uma linha cellular de TEVs humanas de primeiro-trimestre de 
gravidez (linha celular HTR-8/SVneo). Adicionalmente, foi também nosso 
objectivo desenvolver um modelo celular experimental de TEVs insuficientes, 
bem como proceder à reversão desta insuficiência celular melhorando o seu 
estado nutricional. 
Os nossos resultados levaram-nos a concluir que na linha celular HTR-
8/SVneo: a) a captação de GLI parece ser mediada por transportadores 
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facilitativos de glucose 1 (GLUT1), a captação de AA parece ser mediada pela 
sintétase de acil-CoA de cadeia longa (ACSL) 1 e a captação de AF parece ser 
mediada pelo transportador de folatos acoplado a protões (PCFT); b) a 
exposição prolongada (24h) ao xantohumol (XN) interfere com processos 
relacionados com a placentação, dado que reduz a vibilidade, crescimento da 
cultura, proliferação e migração celulares e aumenta a taxa de apoptose 
celular; c) o efeito inibitório do XN relativamente a processos relacionados 
com a placentação é dependente de níveis celulares adequados de GLI e AA, 
dado que o XN inibe a captação celular destes nutrientes e os seus efeitos 
inibitórios nos processos relacionados com a placentação foram revertidos 
com o aumento das concentrações extracelulares de GLI ou AA; e d) o etanol 
(EtOH) e a metformina (METF) inibem a captação celular de GLI e AF, e 
interferem com processos relacionados com a placentação. Relativamente aos 
mecanismos de acção inerentes aos efeitos destes xenobióticos, as seguintes 
vias de sinalização intracelulares parecem estar envolvidas: a) o mammalian 
target of rapamycin (mTOR), cínase c-Jun-N-terminal (JNK) e cínases em 
Tirosina (TK), em relação ao efeito do XN na captação de GLI e AA; b) as vias 
mTOR, JNK e cínase do fosfatidilinositol-4,5-bisfosfato (PI3K), em relação ao 
efeito do EtOH na captação de AF e ainda ao efeito da METF viabilidade 
celular; e c) as vias mTOR e JNK, em relação ao efeito do EtOH na viabilidade 
celular e captação de GLI. 
 Em conclusão, os nossos resultados sugerem que a exposição a 
determinados xenobióticos durante a gravidez poderá afectar a captação de 
nutrientes essenciais à placenta, que pode decorrer em efeitos deletérios ao 
processo de placentação, com consequências prejudiciais ao crescimento e 
desenvolvimento fetais. 
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INTRODUCTION 
 
1. HUMAN PLACENTA 
 
The human placenta is the main interface between the maternal and 
fetal blood circulations [1]. It is a transient organ of fetal origin, which 
performs multiple functions required for the growth and development of the 
fetus, namely: a) anchoring the conceptus to the uterine wall and prevention 
of its rejection by the maternal immune system [1, 2]; b) mediation of the 
exchange of nutrients, respiratory gases, water and waste metabolites 
between maternal and fetal blood [1]; and c) production of hormones which 
can be divided in different functional classes according to , such as steroids (e. 
g. progesterone, oestradiol,  glucocorticoids), polypeptides (e. g. prolactin, 
human placental lactogen, human placental growth hormone), glycoproteins 
(e. g. human chorionic gonadotropin (hCG)), adipokine (e. g. leptin, 
adiponectin, resistin), eicosanoids (e. g. prostaglandins), cytokines (e. g. 
interleukin (IL)-1, IL-6, tumor necrosis factor-alpha (TNF-α)) and growth 
factors (e. g. placenta growth factor, vascular endothelial growth factor 
(VEGF)), that can be secreted into both the fetal and maternal circulations [1-
4].  
 
 
1.1. Placental development – the placentation process  
 
Placentation – formation and growth of the placenta - is a continuous 
and highly regulated process that begins immediately after fertilization and 
ends only after delivery [5]. An adequate placentation and a consequent 
satisfactory nutrient supply to the fetus are crucial factors for fetal 
development and growth and for a good pregnancy outcome. Such critical 
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importance is evident as fetal growth restriction (FGR) and preeclampsia are 
characterized by impaired uterine blood flow and placental development 
causing reduced fetal nutrient uptake and fetal hypoxia [5].  
Early after fertilization, the process of blastocyst implantation begins 
along with the differentiation of trophoblastic stem cells into two cell lineages: 
a) villous cytotrophoblasts (vCTBs) which fuse to form the multinucleated 
syncytiotrophoblast (STB), that ensure placental endocrine, protective and 
transport functions, and b) specialized extravillous trophoblasts (EVTs), 
which are the main participants in the process of placentation (Fig. 1.). EVTs 
are fully specialized trophoblasts exhibiting an invasive and proliferative 
phenotype; they invade the myometrium and uterine vasculature, perform the 
anchorage of the chorionic villi into the uterine wall and actively regulate 
uterine spiral arteries remodeling, a process that ends up with the 
establishment of the utero-placental blood flow [6]. 
 
 
1.2. Cell models of placentation 
 
The HTR-8/SVneo cell line was established 3 decades ago by 
transfecting HTR-8 cells with a plasmid containing the gene for the simian 
virus 40 (SV40) large T antigen (Tag). Thus, similarly to choriocarcinoma cells, 
HTR-8/SVneo cells display an unlimited lifespan in culture. Primary cultures 
of HTR-8 cells were first obtained by the outgrowth of cells from tissue 
explants of normal first trimester villi. These primary cells share features with 
invasive trophoblasts such as expression of cytokeratin (CK) 18 and some 
EVT-specific integrins [7], but they present a limited lifespan in culture. As 
such, the transformed HTR-8/SVneo cell line was established as a human first 
trimester EVTs cellular model. 
- 39 - 
 
 
 
 
 
 
 
 
 
Fig. 1. Formation and differentiation of extravillous trophoblasts. 
During anchorage of chorionic villi at the uterine BM, the mononucleated CTB undergo 
either:  a) fusion and biochemical differentiation to originate the multinucleated 
syncytiotrophoblast/syncytium; or b) originate proliferative CC constituted of 
proliferative and invasive EVTs. BM: basal membrane; CC: cell columns; CTB: 
cytotrophoblast; EVT: extravillous trophoblasts; S: syncytium. Adapted from 
Pollheimer, J. and M. Knofler, Signalling pathways regulating the invasive differentiation 
of human trophoblasts: a review. Placenta, 2005. 26 Suppl A: p. S21-30. 
 
 
HTR-8/SVneo cells possess trophoblastic (secretion of hCG) and 
epithelial (expression of CK 8 and 18) characteristics and they show 
proliferative and invasive characteristics of first-trimester EVTs [7]. 
Therefore, HTR-8/SVneo cells are an accepted in vitro cell model system for 
the study of first-trimester EVTs characteristics [7]. Interestingly, a recent 
study showed that the HTR-8/SVneo cell line contains two distinct 
populations of cells, namely trophoblast and stromal/mesenchymal cells. 
HTR-8/SVneo cell cultures contained few clusters of the 
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trophoblast/epithelial marker CK7 positive cells and the mesenchymal marker 
vimentin positive cells. It is claimed that at the tips of the anchoring villi, 
evCTB undergo a transition from epithelial-to-mesenchymal phenotype, thus 
these cells loose epithelial markers and acquire mesenchymal markers when 
they start to invade and migrate into the maternal endometrium and spiral 
arteries [8]. As such, the fact that the HTR-8/SVneo cell line presents 
stromal/mesenchymal populations of cells might reflect what undergoes in 
vivo during the placentation process. 
There is an assortment of additional EVT cell models, such as SGHPL-4, 
SGHPL-5 and HIPEC 65 cells, that have been developed from first trimester 
placentas after transfection with SV40 large T antigen and express cytokeratin 
7 and HLA-G and retain cellular functions of in vivo EVT (reviewed by [9]). 
However, these cell lines retain a senescence mechanism being commonly 
used only until passage 25, and are suggested to show a fibroblastoid 
phenotype instead of the expected EVT epithelial phenotype (reviewed by 
[9]). Additionally, other existing EVT cell lines (such as HT-116 or SWAN 71) 
have been hardly used for in vitro EVT studies, as their lifespan in culture is 
also limited (reviewed by [9, 10]). So, HTR-8/SVneo cells appears to be the 
most accepted in vitro model system for the study of first-trimester EVTs 
characteristics, including cell fusion, proliferation, migration and invasion. As 
such, our studies will focus on this cell line. 
It is worth of note that, given the important role of EVTs in 
placentation and knowing that FGR is associated with insufficient EVTs, a cell 
model of insufficient EVTs, as observed in FGR, would be crucial in order to 
comprehend the mechanism underlying the normal and abnormal process of 
placentation. Unfortunately, such a model is presently lacking. 
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2. PLACENTAL TRANSPORT OF NUTRIENTS 
 
The placenta plays a major role in fetal nutrition, growth and 
development by transplacental allocation of nutrients from the maternal to 
fetal circulation [11-13]. Furthermore, the placenta itself requires nutrients 
for its own adequate growth and development, and since the majority of 
essential nutrients are not synthesized by the fetus or placenta, at least in 
sufficient amounts, placental nutrient transport from the maternal circulation 
is crucial. It is widely accepted that an impaired capacity of placenta to 
metabolize and supply nutrients to the fetal circulation may be a critical factor 
for the establishment of pregnancy-related pathologies such as preeclampsia 
and FGR [14-16].  
The subject of this study was to characterize transport of the nutrients 
glucose, the long-chain polyunsaturated fatty acids (LC-PUFAs) arachidonic 
(ARA) and docosahexaenoic (DHA) acids, folic acid (FA) and the amino acid L-
methionine (L-Met), to investigate the impact of xenobiotics upon these 
mechanisms and the implications of nutrient uptake modulation on the 
process of placentation, by using a first trimester human EVTs cell line (HTR-
8/SVneo cells). So, in the following section we will describe the central 
principles of glucose, LC-PUFAs, FA and amino acids placental transport. 
 
 
2.1. Glucose Transporters 
 
Glucose is a major substrate for fetal and placental energy metabolism, 
and together with amino acids, it constitutes the primary stimuli for fetal 
secretion of the growth-promoting hormone insulin [17]. Gluconeogenesis in 
the feto-placental unit is minimal [18, 19]; therefore, allocation of glucose 
from the maternal circulation is critical for the process of placentation and for 
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normal fetal development and growth [11, 20]. Despite such importance, 
glucose homeostasis in first-trimester trophoblasts and the implications of 
this mechanism in the process of placentation are still largely unexplored. 
 
 
Fig. 2. Glucose transport in first trimester human trophoblasts. 
Insulin-dependent GLUTs signaling: (1) insulin binds to its receptor leading to 
activation of IRS; (2) activation of PI3K/Akt signaling pathway; (3) trafficking of GSVs 
next to the plasma membrane; (4) tethering/docking and further fusion of GSVs 
containing GLUT4 or 12 with the plasma membrane. Insulin-independent GLUTs 
signaling, most probably GLUT1 and GLUT3. EVT: extravillous trophoblasts; IRS: 
insulin receptors substrate proteins; GLUT: glucose transporter; GSV: GLUT4 (and 
12)-storage vesicle; PM: plasma membrane. 
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Placental transport of glucose was first characterized in syncytial 
microvillous and basal membranes to be sodium-independent, which excludes 
the involvement of the sodium-dependent glucose co-transporters (SGLTs, 
gene symbol SLC5A) (as reviewed elsewhere [11, 21]). On the other hand, 
studies have shown that membrane transporters are selective for D- over L-
glucose and sensitive to inhibition by phloretin (PHT) and cytochalasin B (CYT 
B), pointing thus to the involvement of the facilitative sodium-independent 
sugar transporters [glucose transporter (GLUT) family, gene symbol SLC2A], a 
group comprising at least 14 isoforms (GLUT1–GLUT14) [19, 21, 22]. Among 
the 14 isoforms, GLUT1 is a ubiquitous isoform, expressed in almost all tissues 
and it is regarded as the constitutive form of the glucose transporter in the 
placenta from implantation to term [17, 20-22]. Besides GLUT1, other glucose 
transporters such as GLUT3 and the insulin-sensitive GLUT4 and 12, are found 
in first trimester STB, and play an important role earlier in gestation [11, 22]. 
The insulin-sensitive GLUT4, and hypothetically also GLUT12, are classically 
described in insulin-responsive tissues such as skeletal muscle and adipose 
tissue to be retained in intracellular storage vesicles termed GLUT-storage 
vesicles (GSVs) (reviewed in [23]). Briefly, and as can be observed in Fig. 2, 
insulin binds to its receptor leading to activation of the insulin receptor 
substrate (IRS) proteins. This activates the phosphatidylinositol-3-kinase 
(PI3K)/Akt signaling pathway and subsequent translocation of GLUT4/12 
from GSVs to the plasma membrane occurs,  by tethering/docking of GSVs and 
further fusion with the plasma membrane [23]. GLUT4/12 can be further 
retrieved from the plasma membrane by endocytosis [23]. Regarding GLUT4, 
it is known that: 1) in term TBs, the majority of GLUT4 are localized in low-
density microsomes and its distribution was not altered by insulin treatment 
[11, 24]; 2) GLUT4 has not been identified in membranes from primary STB or 
CTB cells [11, 24]; and 3) GLUT4 levels of expression in JAR choriocarcinoma 
cells were extremely low compared with those of GLUT1 and GLUT3,. Overall, 
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these results suggest that unlike the importance of GLUT4 in first-trimester 
TBs, GLUT4 does not contribute significantly to cellular glucose uptake in term 
TBs [11, 25]. Concerning GLUT12, this isoform is expressed in first-trimester 
STB and vCTB and it is absent at term in these cells, suggesting a vital function 
in early gestation [11, 26]. As for GLUT3, it has been described to be expressed 
in CTB and SCT in early gestation and decreases thereafter, being mainly 
expressed in endothelial cells at term [21, 27]. Curiously, despite the 
recognized deficits in fetal plasma glucose concentrations in FGR fetuses 
(reviewed in [21]), GLUT1 expression in placentas from term or preterm FGR 
appears to be unaffected in this condition (reviewed in [21]). 
 
 
2.2. LC-PUFAs Transporters  
The developing placenta and the fetus require the nutritionally 
essential fatty acids linoleic (LA; 18:2n-6) and γ-linolenic (γ-LNA; 18:3n-3) 
acids, which are obtained predominantly from vegetable oils, and their 
respective long-chain polyunsaturated fatty acids (LC-PUFAs) derivatives, 
arachidonic (ARA; 20:4n-6) and docosahexaenoic acids (DHA; 22:6n-3) [28, 
29]. As reviewed elsewhere [29], ARA is a major precursor for the synthesis of 
eicosanoids such as prostaglandins, thromboxanes and leukotrienes, which 
are important for the development of fetal nervous, visual, immune and 
vascular systems [29, 30] and DHA is crucial for the development of the fetal 
neurovisual system and is highly accumulated in the brain and retina [29, 30]. 
As such, a deficiency of both ARA and DHA during intrauterine life is 
associated with cognitive, behavioral and visual abnormalities later in life 
[31]. In agreement with this, several studies suggest that maternal LC-PUFAs 
supplementation during pregnancy improves neurodevelopmental functions 
of the infants (reviewed in [32]) and, at the same time, reduces the risk of 
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preterm delivery [33]. In fact, studies recommend DHA supplementation when 
less than the desirable maternal plasma levels are achieved through dietary 
habits [34]. Worth of note, alterations in placental LC-PUFAs transport may 
occur in pregnancies complicated by FGR, and fetal-to-maternal blood ratio of 
ARA and DHA was found to be lower in FGR pregnancies compared with 
normal pregnancies [35]. 
LC-PUFAs transported across the human placenta are mainly delivered 
from triglyceride-rich lipoproteins (from which they must be released by the 
action of placental lipases) and from fatty acids bound to albumin [35]. 
Transfer of fatty acids from maternal to fetal circulation may be driven by 
simple passive diffusion [36]. However, in tissues with high fatty acid demand, 
uptake of fatty acids by simple diffusion may be insufficient to meet minimum 
requirements [36]. Although LC-PUFAs cannot be synthesized by the fetus, 
they are present at higher levels in fetal circulation, in relation to maternal 
circulation [36]. This is consistent with an active and selective placental 
transfer of these fatty acids in favor of the fetal compartment – a process 
described as “biomagnification” [36]. At the STB transporting epithelium 
level, both passive diffusion and protein-mediated transport seem to be 
involved in cellular uptake of LC-PUFAs from the maternal circulation, namely 
[30, 37] (Fig. 3.): 
a) placental plasma membrane fatty acid-binding protein (pFABPpm), 
an unidirectional placenta-specific transporter;  
b) ATP-dependent fatty acid transport proteins (FATPs); and  
c) fatty acid translocase (FAT/CD36), a glycoprotein receptor that 
allows bidirectional and non-selective transport of fatty acids 
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Fig. 3. LC-PUFAs transport in first trimester human trophoblasts. 
LC-PUFAs uptake from maternal circulation into the EVTs is mediated by pFABPpm, 
FAT and FATP. It is unknown whether FATP has ACSL1 activity or ACSL1 is active as a 
LC-PUFAs transporter in PM. ACSL1 present in the cytoplasm performs the activation 
of LC-PUFAs in a two-step reaction : 1) an acyl-AMP intermediate is formed from ATP; 
and 2) AMP is then exchanged with CoA to produce the activated acyl-CoA. ACSL1: 
long-chain acyl-CoA synthetases; AMP: adenosine monophosphate; ATP: adenosine 
triphosphate; CoA: coenzyme A; EVT: extravillous trophoblasts; FAT: fatty acid 
translocase; FATP: ATP-dependent fatty acid transport proteins; pFABPpm: plasma 
membrane fatty acid-binding protein; LC-PUFA: long-chain polyunsaturated fatty 
acids; LC-PUFA-CoA: long-chain polyunsaturated fatty acid-coenzyme A; PPi: 
pyrophosphate; PM: plasma membrane. 
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A still ongoing debate about FATP is whether they act solely as 
transport proteins and/or acts in concert with intracellular long-chain acyl-
CoA synthetases (ACSLs) or if FATP itself also harbors ACSL activity [38]. 
ACSLs alone also contribute to the process of LC-PUFAs uptake, as this  group 
of cytosolic enzymes converts LC-PUFAs into acyl-CoA derivatives for further 
esterification or β-oxidation, thus preventing the efflux of the incorporated 
fatty acids [37, 39, 40]. Hence, ACSLs allows the L-PUFAs uptake to be 
unidirectional and trapping them inside the cell [37, 39, 40]. The activation of 
LC-PUFAs by ACSLs requires a two-step reaction (Fig. 3.): 1) an acyl-AMP 
intermediate is formed from ATP; and 2) AMP is then exchanged with CoA to 
produce the activated acyl-CoA [41]. Overall, the precise mechanisms by 
which these transport proteins facilitate the allocation of LC-PUFAs through 
the placenta are still a matter of speculation. 
 
 
2.3. FA Transporters  
 
Folic acid (pteroylglutamate; FA) is the parent structure and oxidized 
form of a large family of B9 family of water-soluble vitamin coenzymes known 
as folates [42-44]. These molecules facilitate the transfer of one-carbon units 
in reactions leading to the synthesis of methionine, thymidine, purine and 
pyrimidine precursors of nucleic acids, the metabolism of certain amino acids, 
and the initiation of protein synthesis in mitochondria [42-44]. FA is of major 
importance for normal fetal development, as evidenced by the well-
established association between maternal folate deficiency and low birth 
weight and increased risk of spontaneous abortion and of neural tube defects 
(NTDs) (e.g. spina bifida and anencephaly) [42-45]. FA importance in 
pregnancy is also demonstrated by the accumulating evidence that 
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supplementation with this vitamin during the periconceptional period can 
reduce the incidence of low birth weight newborns and NTDs [42-45].  
The human placenta expresses:  
a) the reduced folate carrier (RFC1), a folate:organic phosphate 
exchanger that utilizes the transmembrane organic phosphate 
gradient to mediate the uptake of folates and has a maximal activity at 
physiological pH [46-49];  
b) the folate receptor α (FRα) [46, 49, 50] and folate receptor β (FRβ) 
[49, 51], high-affinity folate-binding proteins embedded in the 
membrane by a glycosylphosphoinositol anchor that mediate the 
unidirectional uptake of folates at neutral to mildly acidic pH; and  
c) the more recently described proton-coupled folate transporter 
(PCFT), a high affinity folate:H+ symporter, with an optimal activity at 
acidic pH (5.5–6.0) [49, 52, 53]. PCFT is known to co-localize with FRα 
[49, 52]. 
 
All of these transporters act coordinately to ensure the vectorial 
transfer of folates from maternal to fetal circulation [49, 52, 53]. However, it is 
widely accepted that PCFT and FRα appear to have a major role in the process 
of FA transport from maternal to fetal circulation. In fact, a model for folates 
transport across the placenta has been proposed (Fig. 4.), in which: 1) folates 
bind to FRα; 2) co-localization of this transporter with PCFT allows the 
internalization of both into an endosome; 3) during cytoplasmic transit, this 
endosome is acidified (pH 6.0–6.5) due to an influx of protons through a 
vacuolar proton ATPase, promoting the dissociation of folates from FRα and 
establishing a favorable H+ gradient that allows PCFT-mediated folate efflux 
- 49 - 
 
into the cytoplasm; and 4) FRα and PCFT are then recycled back to the 
membrane surface [49, 53, 54].  
 
Fig. 4. Folic acid transport in first trimester human trophoblasts. 
Model of internalization of PCFT and FRα: (1) folates bind to FRα and FRα with PCFT 
are internalized into endosomes; (2) acidification of the endosome by vacuolar H+-
ATPase; (3) folates are dissociated from FRα and are transported to cytoplasm by 
PCFT-mediated efflux favored by a H+ gradient; (4) FRα and PCFT are recycled back to 
the cell membrane surface. EVT: extravillous trophoblasts; FA: folic acid; FR: folate 
receptor; H+ ATPase: proton ATPase; PCFT: proton-coupled folate transporter; PM: 
plasma membrane; RFC1: reduced folate carrier. 
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Studies by our team showed that placental uptake of FA is PCFT-
mediated and downregulated by chronic hyperglycemia, some anti-
hypertensive drugs, drugs of abuse and ethanol [53], and is differently 
modulated by polyphenols and methylxanthines [55]. Interestingly enough, 
and contrary to the expected, an increase in placental uptake of folates has 
been demonstrated in FGR, suggesting that the placenta exhibited “a 
compensation for the weakness effect" [14].  
 
 
2.4. L-Methionine Transporters 
 
Amino acids are used as building blocks for fetal protein synthesis, and 
are important energy substrates for both the fetus and the placenta [17]. 
Moreover, they are biosynthetic precursors of purines, pyrimidines, some 
neurotransmitters, nitric oxide, glutathione, polyamines and haem [56].  
L-Met is a nutritionally essential large neutral amino acid that plays a 
critical role in one-carbon metabolism. After conversion to S-
adenosylmethionine, this amino acid provides the methyl groups required for 
the methylation of DNA, RNA, proteins, biogenic amines and phospholipids. 
Notably, the importance of L-Met during pregnancy is observed by the higher 
occurrence of NTDs in women with low dietary intake of L-Met, and FGR in 
animal models of L-Met intake restriction during pregnancy [57]. Interestingly 
enough, in placentas obtained from FGR newborns, the activity and expression 
of L-Met transport systems (A, L and y+L, described below) were shown to be 
reduced [32].  
The concentration of most amino acids, including L-Met, at the 
placental level is normally higher than that found in both fetal and maternal 
circulation - a process that can also be described as “biomagnification” (as 
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above described for LC-PUFAs) [56], suggesting that their uptake into the 
placenta occurs mainly by active processes [58], whereas their transport into 
the fetal blood is mainly passive.  
Based on the functional characteristics of amino acid transport 
systems, such as substrate specificity, inhibition by L-Met and placental-
specific location, four different transporters have been identified in the human 
STB as capable of transporting L-Met (Fig. 5.): 
a) the sodium-dependent system A, which mediates the uptake of 
neutral amino acids (both essential- and non-essential) with short and 
unbranched side chains, mostly L-Ala, Gly, L-Ser, L-Met and L-Gln. The 
most commonly expressed isoforms are the sodium-coupled neutral 
amino acids transporter 1 (SNAT1), SNAT2 and SNAT4 [56, 58, 59]; 
b) the sodium-independent system L, which mediates the uptake of 
many neutral (eg. L-Met), branched-chain (eg. L-Leu) and aromatic (eg. 
L-Phe and L-Tyr) amino acids, and includes isoforms with polarized 
expression in the STB, such as L-type amino acid transporter (LAT) 1-4 
[56, 59]; and 
c) the two cationic amino acid transport systems y+L and b0+[56, 59-
61]. 
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Fig. 5. Amino acid transport in first trimester human trophoblasts. 
AA uptake from maternal circulation into the EVTs is mediated by SNAT, LAT, y+L and 
b0+. AA: amino acid; EVT: extravillous trophoblasts; LAT: L-type amino acid 
transporter, PM: plasma membrane; SNAT: sodium-coupled neutral amino acids 
transporter. 
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3. XENOBIOTICS AND PREGNANCY  
 
Pregnant women are frequently exposed to several xenobiotics due to 
lifestyle factors such as diet, medication, smoking, alcohol consumption or 
drug abuse. 
It is widely accepted that the consumption of drugs of abuse, such as 
cocaine (COCA), amphetamines (AMPH), ecstasy (3,4-
methylenedioxymethamphetamine; MDMA), nicotine (NICO) and alcohol 
(ethanol, EtOH) exert deleterious effects on the fetus [62].  
Besides nutrients, diet provides bioactive compounds such as 
polyphenols and methylxanthines, which are present in fruits and vegetables 
and in both alcoholic (red wine, beer) and non-alcoholic (tea) beverages. 
Moreover, pregnant women often take medication for the treatment of 
various pregestational or gestational conditions such as epilepsy, 
hypertension, depression and type 2 and gestational diabetes.  
These families of xenobiotics are known to readily cross the placenta 
[63, 64], and thus the study of their effects upon the placenta and the fetus is 
of major importance. However, the effect of these xenobiotics upon nutrient 
uptake by first trimester human EVTs and upon the placentation process is 
still largely unexplored. 
 
 
3.1. Therapeutic drugs 
 
Fluoxetine (FLUOX) (Fig. 6.) is an antidepressant drug that belongs to 
the selective serotonin reuptake inhibitors (SSRI) class. During pregnancy and 
in the immediate postnatal period, 14-23% of women present a depressive 
disorder [65, 66], and it is estimated that 2–3% of pregnant women receive 
SSRI antidepressant treatment [65]. 
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Metformin (METF) (1,1-dimethylbuguanide hydrochloride) (Fig. 6.) is 
a biguanide agent that reduces hyperglycaemia by suppressing hepatic 
glucose output (hepatic gluconeogenesis), increasing insulin sensitivity and 
improving peripheral glucose uptake [67, 68]. METF is widely used as first-
line treatment in type 2 diabetes and polycystic ovary syndrome (PCOS) [69] 
and is becoming increasingly accepted as an alternative to insulin during 
pregnancy, for the management of type 2 and gestational diabetes and PCOS 
[70-73]. It is worth of note that METF freely crosses the placenta, thus 
exposing the fetus to concentrations approaching those in the maternal 
circulation [69, 74]. However, the effects of METF on the placenta and its long-
term effect on fetal physiology have not been well elucidated [72, 73]. 
 
 
 
 
 
 
 
Fig. 6. Molecular backbone structures of the therapeutic drugs Fluoxetine and 
Metformin. 
 
 
3.2. Drugs of abuse 
 
It is widely accepted that the consumption of drugs of abuse, including 
alcohol (ethanol; EtOH), exerts deleterious effects on the fetus [62]. The 
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placenta and the fetus become frequently exposed to drugs of abuse because 
of maternal use of these drugs. For instance, in an US study, nearly 25% of 
pregnant women had a positive toxicology screen for any illicit drug and 
nearly 10% had a positive screen for COCA, AMPH, MDMA, and/or opiates 
(Fig. 7.) [75]. In relation to EtOH (Fig. 7.), it is one of the most frequently used 
drug worldwide [76], and although studies suggest that most women avoid 
alcohol during pregnancy, in the U.S. population still 10% of pregnant women 
report alcohol use [77]. EtOH is widely accepted as a potent teratogen in 
humans [78, 79] and is one of the most consumed drug of abuse during 
pregnancy [77]. 
 
 
 
 
 
 
 
 
 
Fig. 7. Molecular backbone structures of the drugs of abuse Cocaine, Nicotine, 
Amphetamine, MDMA, Ethanol and Acetaldehyde. 
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Acetaldehyde (ACA) (Fig. 7.) is the principal metabolite of hepatic 
EtOH catabolism (Fig. 8.) and is a highly reactive molecule that can form 
adducts with biological molecules, thus inactivating them. As such, part of the 
toxic effects associated with the ingestion of EtOH is related to ACA formation 
[80]. It is worth to note that EtOH is naturally present in the blood at low 
concentration (0.39 ± 0.45 µg/mL) due to carbohydrate fermentation by the 
bacterial gastrointestinal flora after which it reaches blood circulation by 
simple diffusion from the gastrointestinal tract [80, 81]. Also, there is a still 
on-going debate on the possibility of ethanol formation inside human tissues, 
thus accounting to an ethanol endogenous production [81]. However, from the 
point of view of this study, we will consider this compound as a drug of abuse 
and we will focus on concentration levels superior to the physiologically 
observed.  
 
 
 
 
 
 
 
Fig. 8. Pathways of ethanol metabolism. 
Ethanol is oxidized mainly by cytosolic ADH to acetaldehyde. Another major pathway 
of ethanol metabolism includes its oxidation in microsomes by CYP2E1 and requires 
NADPH instead of NAD+. ADH: alcohol dehydrogenase; CYP2E1: cytochrome P450 
2E1; ER: endoplasmic reticulum; NAD+: nicotinamide adenine dinucleotide; NADPH: 
nicotinamide adenine dinucleotide phosphate; Px: peroxisome. Adapted from Ratna, A. 
and P. Mandrekar, Alcohol and Cancer: Mechanisms and Therapies. Biomolecules, 2017. 
7(3). 
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Alcohol consumption during pregnancy can lead to brain, craniofacial, 
cardiovascular and limb defects collectively termed Fetal Alcohol Spectrum 
Disorders (FASD) [77, 82]. Among children with FASD, a small population 
presents a specific set of anomalies (specific facial abnormalities, fetal growth 
retardation and significant impairments in neurodevelopment) known as 
Fetal Alcohol Syndrome (FAS) [78, 79, 83]. Furthermore, prenatal alcohol 
exposure can lead to other alcohol-related birth defects such as decreased 
immune function, attention problems and hearing impairment, but also 
spontaneous abortion [78]. 
Finally, maternal smoking and exposure to nicotine (NICO) during 
pregnancy may cause FGR [84, 85]. Approximately 14% of U.S. women 
continue to smoke after becoming pregnant [86]. Interestingly enough, NICO 
metabolism increases in pregnancy, which may contribute to the difficulty that 
pregnant women have in quitting smoking [86]. 
 
 
3.3. Dietary bioactive compounds 
 
3.3.1. Polyphenols 
 
In this work we also focused our attention in studying the effects of 
several polyphenols, which are secondary plant metabolites recognized for 
their powerful antioxidant properties [87, 88]. Polyphenols are present in 
several fruits and vegetables and in alcoholic (eg. red wine, beer) and non-
alcoholic (eg. tea, fruit juices) beverages [87, 88]. Polyphenols are chemical 
compounds with more than one hydroxyl functional group (–OH) attached to 
an aromatic ring that underlies the distinctive physical, chemical, and 
biological properties of the particular class members. Polyphenols can be 
classified on two major distinguishable subgroups, flavonoids and non-
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flavonoids, as can be observed in Fig. 9. [88, 89]. Flavonoids consist of 15 
carbon atom compounds (C6–C3–C6) characterized by two benzene rings 
joined by a three carbon chain forming an oxygenated heterocycle [89]. The 
non-flavonoids comprise a more heterogenous group: phenolic acids; phenolic 
alcohols; stilbenes; chalcones; and other polyphenols [89]. Out of the 
polyphenols found in diet, 60% are represented by flavonoids and 30% by 
phenolic acids [87, 89]. 
Several lines of evidence emerged in the last two decades attributing 
health-protective effects to these bioactive substances. Indeed, polyphenols 
are known to have antioxidant, anti-proliferative and anti-inflammatory 
properties, and to be protective against cancer, cardiovascular and 
inflammatory diseases [90, 91]. In this work, we focused our study on the 
polyphenols epigallocatechin-3-gallate (EGCG), quercetin (QUE), resveratrol 
(RESV) and xanthohumol (XN) (Fig. 10.). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Major sub-classes of flavonoid and non-flavonoid polyphenols. 
Adapted from Teixeira, J., et al., Dietary Polyphenols and Mitochondrial Function: Role in 
Health and Disease. Curr Med Chem, 2017; 24: 1-27. 
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EGCG (epigallocatechin-3-gallate) is the ester of epigallocatechin and 
gallic acid, and is the most abundant type of catechin in tea (e.g. green and 
white tea) [92]. QUE (3,3′,4′,5,7-pentahydroxyflvanon) is categorized as a 
flavonol and is found in a variety of foods including apples, onions, berries, 
grapes, shallots, tea, and tomatoes, as well as in many seeds, nuts, flowers, 
barks, and leaves [93]. RESV (3, 4’, 5-trihydroxystilbene) is a stilbenic phenolic 
compound, present mainly in grape and grape products, but also in lower 
amounts in peanuts, pistachios, some berries, tomato skin, and chocolate [91]. 
XN (3’-[3,3-dimethyl allyl]-2’,4’,4-trihydroxy-6’-methoxychalcone) – is a 
structurally simple prenylated chalcone that occurs in the hop plant and is 
used to add bitterness and flavor to beer [94].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Molecular backbone structures of the polyphenols Quercetin, 
Epigallocatechin-3-gallate, Resveratrol and Xanthohumol.  
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Worth to note that most polyphenols, except catechins, can exist in the 
diet as glycosides (such as glucoside, galactoside, rhamnoside, arabinoside, 
and rutinoside) and are considered too hydrophilic for absorption by passive 
diffusion in the small intestine, thus only aglycones or the resulting aglycones 
from hydrolyzation (deglycosylation) of the glycoside form were likely to be 
absorbed [95]. Interestingly enough, some studies point to the possibility that 
the glycoside form of the polyphenols might be actively transported across the 
enterocyte [95].   
 
3.3.2. Methylxanthines 
Methylxanthines such as caffeine (1,3,7-trimethylxanthine, CAF) and 
its demethylated metabolite theophylline (1,3-dimethylxanthine, TEO) rank as 
one of the topmost commonly consumed dietary ingredients throughout the 
world [96, 97] (Fig. 11.). Drinks containing CAF and TEO (e.g. coffee, tea, soft 
drinks) are often consumed by pregnant women; indeed, 75% of pregnant 
women in the US consume low to moderate amounts of CAF [98]. Both CAF 
and TEO readily pass the placenta barrier [64] and thus might affect the fetus, 
as the immature fetal liver enzyme CYP3A4 is unable to metabolize them [99]. 
Thus, their effect on the placenta and fetus should be explored. The FDA 
recommends that pregnant women should avoid the ingestion of CAF due to 
observed teratogenic effects (e.g. spontaneous abortion and FGR) [98, 100]. 
However, there is still some debate as to the CAF real detrimental effect to the 
fetus, mostly due to confounding associated maternal risk behavior factors, 
such as tobacco use [63, 101, 102]. For this reason, CAF present in coffee and 
commonly consumed by pregnant women, and its metabolite TEO, are two 
xenobiotics whose placental effects are worth of study. 
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Fig. 11. Molecular backbone structures of the methylxanthines Caffeine and 
Theophylline. 
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4. THE PLACENTA AS A NUTRIENT SENSOR 
 
The placenta responds to perturbations in the maternal environment 
(e.g. hypoxia, stress, obesity, diabetes, toxins, altered nutrition), thereby being 
proposed to act as a nutrient sensor [103-106]. Indeed, the placenta performs 
an active response to nutrient deprivation by suppressing nonessential 
energy-demanding processes. This occurs mainly by regulating the transport 
capacity of nutrients in response to maternal or fetal stimuli [103-106]. 
According to this model, in response to a maternal undernutritional status, 
like maternal nutrient restriction (which induces FGR), the placenta up-
regulates nutrient transport (through nutrient-sensing signaling pathways) 
[103-106].  
Interestingly enough, emerging evidence suggests that the intracellular 
signaling pathway mammalian target of rapamycin (mTOR) - and its up-
stream regulator protein kinase B (AKT) - plays a central role as a placental 
nutrient-sensing mechanism [103-106]. mTOR regulates cell metabolism in 
response to altered nutrient levels and is influenced by a large number of 
upstream regulators such as amino acids [105, 107, 108], folate [105, 109], 
growth factors [104, 107], and free fatty acids [104, 107], which are likely to 
be affected by maternal nutrition [103-106]. Also, mTOR is central to the 
regulation of cell proliferation with input from the AKT pathway, being these 
pathways usually considered together as AKT-mTOR system [106]. 
mTOR is a serine/threonine protein kinase and comprises two major 
protein complexes: mTORC (mTOR complex) 1 and 2, which share the same 
core kinase but have different adaptor proteins, raptor and rictor, respectively 
[103, 110]. mTORC1 regulates cell growth, proliferation, and metabolism and 
mTORC2 regulates cytoskeletal organization and cellular metabolism [103]. 
Mechanistically, as seen in Fig. 12., mTORC1 has a direct effect upon cell 
proliferation due to the promotion of translation through the phosphorylation 
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of eukaryotic initiation factor 4E-binding proteins (4E-BP1 and 4E-BP2) and 
ribosomal S6 kinases (S6K1 and S6K2) [111], whereas mTORC2 activates AKT 
- serine/threonine protein kinase - through phosphorylation [112, 113].  
 
 
Fig. 12. Placental mTOR as a nutrient sensing signaling pathway. 
mTORC2 activates AKT through phosphorylation. Akt activates mTORC1, which has a 
direct phosphorylation effect of 4E-BP1 and S6Ks. This seems to promote cell 
proliferation, growth and nutrient transport into the cell. Akt: protein kinase B; 4E-BP: 
4E-binding proteins; mTORC: mTOR complex; PM: plasma membrane; S6K: ribosomal 
S6 kinases. 
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Glucose availability might regulate mTOR signaling through energy 
production in the form of ATP: low ATP levels (with accumulation of ADP and 
AMP) activate AMPK (AMP activated protein kinase) and this leads to mTOR 
inactivation [114], either by direct inhibitory action on raptor or by 
stimulation of the tuberous sclerosis complex (TSC1/2) [106], a major 
upstream regulator of mTORC1. 
Amino acid availability also regulates mTORC1, as experiments with 
amino acid withdrawal, in particular L-Leu, led to inhibition of mTOR, growth 
restriction, and stimulation of autophagy [106]. On the other hand, the mTOR 
pathway in the human placenta stimulates the activity of system L [115], 
system A and taurine amino acid transporters [108] at the posttranslational 
level by influencing translocation to the apical membrane [108].  
In relation to folate, mTORC1 and mTORC2 regulate cellular folate 
uptake in primary human trophoblast cells. Indeed, mTORC1 or mTORC2 
inhibition markedly decreased the abundance of folate transporters RFC and 
FRα, but not PCFT [116]. 
In summary, the mTOR/AKT signaling pathway has been pointed as a 
novel regulator of placental growth and development. As reviewed by 
Dimasuay et. al. [103], protein restriction in rats and nutrient restriction in 
baboons resulted in inhibition of placental mTORC1 activity. On the other 
hand, placental mTOR is activated in animal models of maternal obesity and in 
obese women delivering large-for-gestational age (LGA) babies [103]. Also, in 
rats fed a low-protein diet, a reduction of mTOR activity, along with reduced 
insulin and AKT signaling was observed [117]. In contrast, an obesogenic diet 
has been shown to cause activation of mTOR in rat placentas [118], while the 
contrary was found after overnutrition in sheep and mice fed an obesogenic 
diet [119, 120]. Moreover, treatment of mouse blastocysts with rapamycin or 
knockout of mTOR leads to lethality at E5.5 associated with a failure of 
trophoblast outgrowth [121, 122]. Interestingly, knockout of Akt1 causes 
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placental and FGR in the mouse [123]. As a whole, these observations show 
that, although involvement of mTOR and Akt appears to exist, the nutrient 
sensing function of the placenta and its consequences upon the placentation 
process and placental growth are still not completely understood, being 
presently an attractive area of research. 
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AIMS 
 
The main aim of this study was to investigate the effect of xenobiotics 
upon first-trimester placental nutrient transport and its correlation with the 
placentation process. We also intended to develop an experimental cellular 
model of insufficient human first trimester EVTs, as observed in FGR, which is 
presently lacking.  
According to these purposes this work are divided in the following 
chapters:  
 
 
CHAPTER I - Modulation of GLU transport and placentation-related 
processes in a human first-trimester EVTs cell line (HTR-8/SVneo cells) 
Given the importance of GLU as a critical nutrient for the placenta and fetal 
nutritional status, we intended to: 
 characterize the uptake of 3H-2-deoxy-D-glucose (3H-DG), D-glucose 
analog efficiently transported by GLUT family members,  by HTR-
8/SVneo cells 
 investigate the modulation of 3H-DG uptake by exposure to several 
distinct xenobiotics  
 investigate whether the effect of XN, EtOH and METF on uptake of 3H-
DG involved some specific intracellular signaling pathways  
 investigate the putative correlation between modulation of uptake of 
3H-DG by XN and placentation-related properties (viability, 
proliferation, culture growth and migration) of HTR-8/SVneo cells 
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CHAPTER II – Modulation of LC-PUFAs transport and placentation-
related processes in a human first-trimester EVTs cell line (HTR-
8/SVneo cells) 
Given the importance of LC-PUFAs as essential nutrients for the placenta and 
fetal nutritional status, we intended to: 
 characterize the uptake of 14C-ARA and 14C-DHA 
 investigate modulation of 14C-ARA and 14C-DHA uptake by XN 
 investigate whether the effect of XN on uptake of 14C-ARA involved 
some specific intracellular signaling pathways  
 study the putative correlation between modulation of uptake of 14C-
ARA by XN and placentation-related properties (viability, 
proliferation, culture growth, migration and apoptosis) of HTR-
8/SVneo cells 
 
 
CHAPTER III – Modulation of FA transport in a human first-trimester 
EVTs cell line (HTR-8/SVneo cells) 
Given the importance of FA as a critical nutrient for the placenta and fetal 
nutritional status, we intended to: 
 characterize the uptake of 3H-FA 
 investigate the modulation of uptake of 3H-FA by XN, EtOH and METF 
 investigate whether the effect of XN, EtOH and METF on uptake of 3H-
FA involved some specific intracellular signaling pathways 
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CHAPTER IV – Modulation of L-MET transport in a human first-trimester 
EVTs cell line (HTR-8/SVneo cells) 
Given the importance of L-MET as a critical nutrient for the placenta and fetal 
nutritional status, we intended to: 
 characterize the uptake of 14C-L-MET  
 investigate the modulation of uptake of 14C-L-MET by XN 
 
 
CHAPTER V – Modulation of placentation-related processes in a human 
first-trimester EVTs cell line (HTR-8/SVneo cells) 
Given that the placenta is exposed to a plethora of xenobiotics that might alter 
nutrient transport as well as the process of placentation, we intended to: 
 investigate modulation of placentation-related processes such as cell 
viability, proliferation, culture growth, migration and apoptosis index 
by a plethora of xenobiotics 
 investigate the involvement of some intracellular signaling pathways 
on the cytotoxic and antiproliferative effect of EtOH and METF 
- 72 - 
 
- 73 - 
 
CHAPTER I  
 
Modulation of GLU transport and placentation-related processes in a 
human first-trimester EVTs cell line (HTR-8/SVneo cells) 
 
The information contained in this chapter is included in the following original 
publications:  
 
 
Manuscript A. Correia-Branco A, Azevedo CF, Araujo JR, Guimaraes JT, Faria 
A, Keating E and Martel F. Xanthohumol impairs glucose uptake by a 
human first-trimester extravillous trophoblast cell line (HTR-8/SVneo 
cells) and impacts the process of placentation. Molecular Human 
Reproduction, 2015, 21(10):803-815 
 
Molecular Human Reproduction (Mol Hum Reprod) 
DOI: 10.1093/molehr/gav043 
IF: 3.585 
 
 
Manuscript B. Correia-Branco A, Keating E and Martel F. Involvement of 
mTOR, JNK and PI3K in the negative effect of ethanol and metformin on 
the human first-trimester extravillous trophoblast HTR-8/SVneo cell 
line. European Journal of Pharmacology, 2018 (accepted).  
 
European Journal of Pharmacology (Eur J Pharmacol) 
DOI: 10.1093/molehr/gav043 
IF: 2.896 
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Manuscript A. Correia-Branco A, Azevedo CF, Araujo JR, Guimaraes JT, Faria 
A, Keating E and Martel F. Xanthohumol impairs glucose uptake by a 
human first-trimester extravillous trophoblast cell line (HTR-8/SVneo 
cells) and impacts the process of placentation. Molecular Human 
Reproduction, 2015, 21(10):803-815. 
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CHAPTER II 
 
 
Modulation of LC-PUFAs transport and placentation-related processes in 
a human first-trimester EVTs cell line (HTR-8/SVneo cells) 
 
The information contained in this chapter is included in the following original 
publication:  
 
 
Manuscript C. Correia-Branco A, Keating E and Martel F. Arachidonic Acid 
Reverses Xanthohumol-Induced Insufficiency in a Human First-
Trimester Extravillous Trophoblast Cell Line (HTR-8/SVneo Cells). 
Reproductive Sciences. 2017: 1933719117746762. 
 
Reproductive Sciences (Reprod Sci) 
DOI: 10.1177/1933719117746762 
IF: 2.443 
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Reverses Xanthohumol-Induced Insufficiency in a Human First-
Trimester Extravillous Trophoblast Cell Line (HTR-8/SVneo Cells). 
Reproductive Sciences. 2017: 1933719117746762. 
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CHAPTER III 
 
 
Modulation of FA transport in a human first-trimester EVTs cell line 
(HTR-8/SVneo cells) 
 
The information contained in this chapter is included in the following original 
publication:  
 
 
Manuscript B. Correia-Branco A, Keating E and Martel F. Involvement of 
mTOR, JNK and PI3K in the negative effect of ethanol and metformin on 
the human first-trimester extravillous trophoblast HTR-8/SVneo cell 
line. European Journal of Pharmacology, 2018 (accepted).  
 
European Journal of Pharmacology (Eur J Pharmacol) 
DOI: 10.1093/molehr/gav043 
IF: 2.896 
 
 
Manuscript C. Correia-Branco A, Keating E and Martel F. Arachidonic Acid 
Reverses Xanthohumol-Induced Insufficiency in a Human First-
Trimester Extravillous Trophoblast Cell Line (HTR-8/SVneo Cells). 
Reproductive Sciences. 2017: 1933719117746762. 
 
Reproductive Sciences (Reprod Sci) 
DOI: 10.1177/1933719117746762 
IF: 2.443 
 
 
- 142 - 
 
 
 
 
 
 
 
- 143 - 
 
CHAPTER IV 
 
 
Modulation of L-MET transport in a human first-trimester EVTs cell line 
(HTR-8/SVneo cells) 
 
The information contained in this chapter is included in the following original 
publication:  
 
 
Manuscript C. Correia-Branco A, Keating E and Martel F. Arachidonic Acid 
Reverses Xanthohumol-Induced Insufficiency in a Human First-
Trimester Extravillous Trophoblast Cell Line (HTR-8/SVneo Cells). 
Reproductive Sciences. 2017: 1933719117746762. 
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DOI: 10.1177/1933719117746762 
IF: 2.443 
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CHAPTER V 
 
 
Association of modulation by xenobiotics of placentation-related 
processes with altered placental transport of nutrients, in a human first-
trimester EVTs cell line (HTR-8/SVneo cells) 
 
The information contained in this chapter is included in the following original 
publications:  
 
 
Manuscript D. Correia-Branco A, Keating E and Martel F. Placentation-
related processes in a human first-trimester extravillous trophoblast cell 
line (HTR-8/SVneo cells) are affected by several xenobiotics. Drug and 
Chemical Toxicology, 2018, 1-5.  
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DOI: 10.1080/01480545.2018.1463240 
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DISCUSSION AND CONCLUSIONS 
 
 
CHAPTER I - Modulation of GLU transport and placentation-related 
processes in a human first-trimester EVTs cell line (HTR-8/SVneo cells) 
 
The results presented in Chapter I describe the functional 
characteristics of glucose uptake by HTR-8/SVneo cells, as well as its 
modulation by short-term exposure to xenobiotics. This chapter also includes 
the studied the modulation of glucose uptake by long-term exposure to XN and 
the impact in the process of placentation as assessed by the placentation-
related processes viability, proliferation, culture growth and migration of 
HTR-8/SVneo cells. We additionally investigated the modulation of glucose 
uptake by long-term exposure to EtOH and METF. 
To accomplish this, and as described in Manuscript A, we first 
characterized glucose uptake. For these experiments, 3H-DG was used. This 
compound is a D-glucose analog efficiently transported by GLUT family 
members, but a very poor SGLT substrate [124], and it is not metabolized by 
phosphoglucose isomerase [125]. Our results indicated that 3H-DG uptake by 
HTR-8/SVneo cells was as expected sodium-independent (see Introduction, 
section 2.1.), thus excluding the involvement of the SGLTs family. Moreover, 
3H-DG uptake by HTR-8/SVneo cells was mainly insulin-insensitive, saturable 
and inhibited by the GLUT inhibitors CYT B, PHT and PHZ. These 
characteristics led us to conclude that a GLUT transporter is the main 
mediator of glucose uptake by HTR-8/SVneo cells, that most probably 
corresponded to GLUT1 since this transporter is highly expressed in this cell 
line [126] and it is known to be critical for glucose uptake in placenta 
throughout pregnancy [21]. It is worth to note that although PHZ is classically 
described as a specific inhibitor of SGLTs [127], it has been described by our 
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group to inhibit also GLUTs [128, 129]. Because we here show that 3H-DG 
uptake by HTR-8/SVneo cells was sodium-independent and excluded the 
SGLTs family, we can conclude that PHZ effect upon 3H-DG uptake is related to 
GLUTs inhibition. 
Next, given the importance of glucose in pregnancy (see Introduction, 
section 2.1.) and the scarce knowledge on glucose uptake modulation in first-
trimester EVTs, we investigated modulation of 3H-DG uptake by short-term 
(30 min) exposure to xenobiotics. As described previously (see Introduction, 
section 3.), the xenobiotics tested in the context of this study are frequently 
consumed during pregnancy [63, 64], and thus the study of their effects upon 
3H-DG uptake by the placenta is of major importance. These were: a) the 
therapeutic drugs FLUOX and DEXA; b) the drugs of abuse AMPH, MDMA, 
COCA, NICO and EtOH; and c) the dietary bioactive compounds EGCG, XN, QUE, 
RESV, CAF and TEO.  
We observed that, among the compounds tested, FLUOX and DEXA 
reduced 3H-DG uptake in a concentration-independent manner. A short-term 
exposure to the drugs of abuse AMPH, MDMA, COCA, NICO and EtOH did not 
affect 3H-DG uptake by HTR-8/SVneo cells. Regarding the dietary bioactive 
compounds, the polyphenols QUE, EGCG, XN and RESV, and the 
methylxanthines CAF and TEO induced a concentration-dependent inhibition 
of 3H-DG uptake. Of these, XN was found to be the most potent inhibitor of 3H-
DG uptake (IC50 of 3.55 µM). XN showed up to be a non-competitive inhibitor, 
since it decreased Vmax without affecting the transporter affinity for 3H-DG 
(Km). These first results led us to conclude that 3H-DG uptake by HTR-8/SVneo 
cells is susceptible to modulation by distinct therapeutic drugs and bioactive 
dietary compounds present in commonly consumed alcoholic and non-
alcoholic beverages (e.g. beer, green tea and coffee). We further studied the 
effect of long-term exposure to XN upon 3H-DG uptake, since this polpyphenol 
was the most potent inhibitor of the transport process. In a long-term 
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exposure to XN inhibited 3H-DG uptake and, similarly to its short-term effect, it 
showed up to be a non-competitive inhibitor (decreasing Vmax while not 
affecting the Km of 3H-DG uptake). This effect was associated neither with a 
decrease in GLUT1 mRNA expression levels nor with a decrease in GLUT1 
protein levels, suggesting that the reduction of 3H-DG transport induced by XN 
is related to changes in the intrinsic activity of the GLUT1 transporter. 
Furthermore, the inhibitory effect of long-term exposure to XN upon 3H-DG 
uptake was found to be reversed by the tyrosine kinases (TKs) inhibitor 
genistein (10 mM), the c-Jun N-terminal kinases (JNK) inhibitor SP 600125 (5 
mM) and mTOR inhibitor rapamycin (RAPA, 100 nM) but not by the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor LY 294002 (1 
µM), thus indicating the involvement of TKs, JNK and mTOR intracellular 
pathways, but not PI3K, in the effect of XN. The fact both JNK and mTOR 
intracellular signaling pathways are both involved in the XN effect upon 3H-DG 
uptake is not surprising as both have already been described to regulate each-
other in synergy as a response to cellular stresses[130]. It is important to note 
that, as described in Introduction (section 4.), mTOR signaling pathway is 
considered a central nutrient sensor, is downregulated by glucose restriction 
[114] and is also downregulated in FGR placentas [103, 106]. Moreover, it is 
worth to note that to the present moment, very little is known regarding the 
effect of XN upon the here studied. Indeed, we found only a study by Deeb at. 
al., that shows that in prostate cancer cells, XN is associate with the inhibition 
of the intracellular signaling pathways Akt, NF-κB and mTOR, thus pointing to 
the same inhibitory effect we observed upon mTOR [131].    As such, our 
studies contribute to the knowledge of the effect of the polyphenol XN upon 
such important intracellular signaling pathways as mTOR.  
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Fig. 13. Effect of xanthohumol, ethanol and metformin upon glucose uptake and 
placentation-related properties by HTR-8/SVneo cells. 
Inhibitory effect of XN, EtOH and METF upon 3H-DG uptake mediated by GLUT1/3. 
Lactate resulting from the process of glycolysis is transported to the extracellular 
medium by MCT4 and XN inhibits the re-uptake of lactate mediated by MCT1. XN 
inhibits TK, JNK and mTOR. EtOH inhibits TK and mTOR intracellular signaling 
pathways, which seems to be involved in the 3H-DG uptake mediated by GLUT1/3. XN, 
EtOH and METF impair placentation-related properties whilst GLU seems to 
ameliorate these properties. EtOH: ethanol; EVT: extravillous trophoblasts; GLUT: 
glucose transporter; MCT: monocarboxylate transporter; METF: metformin; mTOR: 
mammalian target of rapamycin; PCFT: proton-coupled folate transporter; PM: plasma 
membrane; TK: tyrosine kinases; XN: xanthohumol. 
 
Next, we observed that both short- and long-term exposure to XN 
induced an unexpected increase in extracellular lactate levels. These results 
are interesting as XN inhibited 3H-DG uptake, thus, it would be expected a 
- 161 - 
 
reduction in a glycolysis product such as lactate unlike the results observed.  
As such, we hypothesized that XN could be impairing the reuptake of 
extracellular lactate by inhibiting the lactate transporter monocarboxylate 
transporter 1 (MCT1). In order to verify this, we studied the effect of XN on 
the uptake of the known MCT1 substrate butyrate. We confirmed that uptake 
of butyrate (14C-BT) was significantly reduced after exposure to XN. Thus, we 
conclude that exposure to XN inhibits MCT1-mediated uptake of lactate, which 
may also starve cells of lactate (Fig. 13.). 
 
Regarding the effect of XN upon placentation-related processes, we 
verified that a long-term exposure to XN impairs placentation-related 
processes such as cell viability, culture growth, proliferation and migration 
(Fig. 13.). Importantly, we showed that low extracellular glucose mimics the 
effect of XN upon cell viability and culture growth – albeit not its effect upon 
cell migration - and that high extracellular glucose reversed these nefarious 
effects of XN upon cell viability and culture growth. As such, we can conclude 
that the anti-proliferative and cytotoxic effects of XN are dependent upon 
glucose deprivation of HTR-8/SVneo cells. These results point to an 
interesting application of XN to induce EVTs insufficiency and thus to mimick 
FGR, as EVT insufficiency, characterized by shallow cellular viability, 
proliferation, migration, invasion and angiogenesis, is believed to be an 
underlying mechanism of FGR [132]. 
 
In the next part of Chapter I, as described in Manuscript B, we 
characterized the long-term effect of the drug the abuse EtOH and the 
therapeutic drug METF upon glucose uptake by HTR-8/SVneo cells. Alcohol 
use during pregnancy is associated with increased maternal and (or) fetal 
morbidity and mortality, higher risk of low birth weight, preterm delivery and 
teratogenesis [133, 134]. More alarming, in a prospective study from the years 
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2000 to 2012 including 5,036 pregnant women, 55% reported alcohol use in 
the first trimester [135]. We observed that long-term exposure (24 h) to EtOH 
(1-100 µM) concentration-dependently inhibited 3H-DG uptake by HTR-
8/SVneo cells. In line with this observation, previous studies from our group 
demonstrated that a 48h-exposure to EtOH reduced 3H-DG uptake by the 
choriocarcinoma cell line BeWo [136]. Furthermore, the inhibitory effect of 
long-term exposure to EtOH (100 μM) upon 3H-DG uptake was reversed by the 
mTOR inhibitor RAPA (100 nM) and by the JNK inhibitor SP600125 (5 µM), 
but not by the PI3K inhibitor LY294002 (1 µM) (Fig. 13.). This indicates the 
involvement of mTOR and JNK, but not the PI3K, intracellular signaling 
pathways in this EtOH effect. METF is widely used as first-line treatment in 
type 2 diabetes and PCOS [69] and is becoming increasingly accepted as an 
alternative to insulin during pregnancy, for the management of type 2 and 
gestational diabetes and PCOS [70-73]. Interestingly, we observed that long-
term exposure (24 h) to METF (0.01-1 mM) concentration-dependently 
inhibited 3H-DG uptake by HTR-8/SVneo cells (Fig. 13.). METF is described as 
an antihyperglycemic drug involved in the stimulation of GLU uptake by cells, 
thus METF inhibiting 3H-DG uptake by HTR-8/SVneo cells is an unexpected 
result. However, it is of major importance to note that GLUT4 has been 
described to be activated by METF in order to increase the GLU uptake by 
human adipocytes [137], and as above described in Manuscript A, 3H-DG 
uptake by HTR-8/SVneo cells is insulin-independent and is not mediated by 
GLUT4, thus providing an explanation to the fact that in this study METF 
inhibiting 3H-DG uptake. These results point to a potential harmfulness of this 
therapeutic drug upon the placentation process and to insufficient nutrient 
supply to the placenta and the fetus. Furthermore, the effect of METF (1 mM) 
was not affected by mTOR, JNK and PI3K inhibitors, excluding the involvement 
of these intracellular signaling pathways in the effects of METF. These results 
are interesting as METF has previously been described to decreased 
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proliferation of human endometrial cancer by inhibiting PI3K/AKT/mTOR 
signaling [138]. Overall, these results are interesting, because as above 
described, mTOR signaling pathway is a central nutrient sensor, and mTOR 
seems to be involved in XN and EtOH long-term inhibitory effects upon 
glucose uptake by HTR-8/SVneo cells. 
Interestingly enough, we observed (Manuscript B) that both EtOH, its 
metabolite ACA and METF presented a potent antiproliferative, cytotoxic and 
antimigratory effect in HTR-8/SVneo cells (Fig. 13.). Furthermore, as expected 
and as already described elsewhere for this cell line [139, 140], EtOH 
markedly induced cellular apoptosis of HTR-8/SVneo cells. METF also 
exhibited proapoptotic effect in HTR-8/SVneo cells. Altogether, these results 
suggest that both EtOH and METF present a harmfulness during pregnancy. 
However, it is not possible to confirm whether their inhibitory effect upon 
placentation-related processes here studied are dependent on inhibition of 
uptake of GLU and FA (as described in Chapter I and Chapter III). 
 
 
 
CHAPTER II – Modulation of LC-PUFAs transport and placentation-
related processes in a human first-trimester EVTs cell line (HTR-
8/SVneo cells) 
 
Knowing the above described inhibitory effect of XN upon 3H-DG 
uptake and upon placentation-related processes (cell viability, culture growth, 
proliferation and migration), we decided to investigate the effect of this 
compound on the placental uptake of other nutrients, as well as its 
implications upon the above mentioned placentation-related processes. So, 
the results presented in Chapter II describe the functional characteristics of 
the uptake of the essential nutrients ARA and DHA by HTR-8/SVneo cells, as 
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well as its modulation by short- and long-term exposure to XN. Next, we 
studied the modulation of ARA uptake by long-term exposure to XN and its 
impact in the process of placentation as assessed by the placentation-related 
processes viability, proliferation, culture growth, migration and apoptosis of 
HTR-8/SVneo cells. 
In this part of the work, as observed in Manuscript C, we studied the 
effect of short-term exposure to XN upon ARA and DHA uptake by HTR-8/SV 
neo cells. Short-term exposure to XN inhibited the uptake of 14C-ARA and 14C-
DHA in a concentration-dependent manner. In a more detailed 
characterization of the uptake of 14C-ARA, we showed that this process was 
strongly depended on the activity of ACSL, as it was markedly inhibited by 
triacsin C (~75%), a potent inhibitor of ACSL activity [39]. These results are in 
good agreement with reported data obtained in primary cultured human term 
TBs and in cellular model of term human STB, the Bewo cells [37, 39, 40]. 
Although simple diffusion is considered quantitatively less important than the 
above referred protein-mediated transport of fatty acids [37, 141, 142], 
protonation of 14C-ARA and thus simple diffusion of this fatty acid transport 
across the membrane lipid bilayer also appears to contribute to 14C-ARA 
uptake by HTR-8/SVneo cells, because we observed an increase in 14C-ARA 
transport with decreasing pH. 
We next verified that long-term exposure to XN also inhibited 14C-ARA 
uptake in a concentration-dependent manner. XN also inhibited 14C-DHA 
uptake, but not in a concentration-dependent manner. Regarding the effect of 
a long-term exposure of XN upon 14C-ARA uptake, XN showed up to be an 
uncompetitive inhibitor, as it reduced both Vmax and Km of 14C-ARA uptake. 
Additionally, we verified that the intracellular signaling pathways TK, JNK and 
mTOR are involved in the inhibitory effect of XN upon 14C-ARA uptake, 
similarly to what we described in Chapter I regarding glucose uptake [143]. 
Long-term exposure to XN also reduced the expression of ACSL1, an effect that 
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was prevented by high extracellular ARA (Fig. 14.), but not by the PPAR-γ 
agonist rosiglitazone (RG). 
 
Next, in Manuscript C, we investigated modulation of ARA uptake by 
long-term exposure to XN and correlation of this effect with placentation-
related processes such as cell viability, proliferation, culture growth, 
migration and apoptosis index. According to data already observed in 
Manuscript A, XN impaired placentation-related processes, by showing a 
cytotoxic, antiproliferative, antimigratory and proapoptotic effect (Fig. 14.). 
Importantly, all these effects were prevented by high extracellular ARA, but 
not by the PPAR-γ agonist rosiglitazone (RG). Interestingly, a long-term 
exposure of HTR-8/SVneo cells to XN leads to a similar phenotype as observed 
in insufficient EVTs from pregnancy-related pathologies such as FGR. So, XN 
exposure could provide a means to develop an experimental cell model of 
first-trimester insufficient EVTs. It is worth of note that, besides the culture of 
cell lines, it would be appropriate to study placentation-related processes such 
as EVTs proliferation, invasion and migration by using primary cell models, as 
isolated by the Kliman method [144]. This, however, is hampered by fact that: 
a) the amount of primary trophoblasts is limited; b) cultures may be 
contaminated with other placental cell types such as fibroblasts; and c) in 
Portugal, the access to normal first-trimester placentas is strongly limited. In 
Portugal, the termination of pregnancy is permitted according to the law 
number 16/2007, but when performed by the National Health System 
(Sistema Nacional de Saúde, SNS), the main procedure is mainly realized at 
home with legal medication, which invalidates either the viability of the 
explants and also the sterilized status required.  As such, the experimental cell 
model of first-trimester insufficient EVTs that we here propose is, for the time 
being, the best approach to study EVTs insufficiency. 
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Fig. 14. Effect of xanthohumol upon arachidonic acid uptake and upon 
placentation-related properties on HTR-8/SVneo cells.  
Inhibitory effect of XN upon 14C-ARA uptake mediated by ACSL1. XN inhibits TK, JNK 
and mTOR intracellular signaling pathways, which seems to be involved in the 14C-
ARA uptake mediated by ACSL1. XN impairs placentation-related properties and 
ACSL1 expression whilst ARA seems to ameliorate these properties. ACSL1: long-chain 
acyl-CoA synthetases; ARA: arachidonic acid; EVT: extravillous trophoblasts; FATP: 
ATP-dependent fatty acid transport proteins; mTOR: mammalian target of rapamycin; 
PM: plasma membrane; TK: tyrosine kinases; XN: xanthohumol. 
 
 
Altogether, the results regarding the effect of long-term exposure to 
XN upon nutrients uptake and modulation of placentation-related processes, 
obtained in Chapter I and II (with the results from Manuscript A and 
Manuscript C), led us to conclude that we have developed an experimental 
cell model of first-trimester insufficient EVTs. In fact, long-term exposure of 
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HTR-8/SVneo cells to XN lead to a similar phenotype as observed in 
insufficient EVTs from pregnancy related pathologies such as FGR. XN was 
able to impair the pro-placentation properties cell viability, proliferation, 
culture growth and migration and increased apoptosis in a GLU- or ARA-
dependent manner, with involvement of TK, JNK and mTOR intracellular 
signaling pathways. We were also able to revert these detrimental effects by 
increasing the extracellular levels of these essential nutrients. This also points 
to the critical importance of both GLU and ARA during pregnancy, particularly 
during the first-trimester of pregnancy. Moreover, a central signaling pathway 
involved in the XN effects is mTOR, which also reinforces its key role as a 
nutrient sensor. 
 
 
 
CHAPTER III – Modulation of FA transport in a human first-trimester 
EVTs cell line (HTR-8/SVneo cells) 
 
The results presented in Chapter III describe the functional 
characteristics of the uptake of folic acid by HTR-8/SVneo cells, as well as its 
modulation by short-term exposure to XN and its modulation by long-term 
exposure to XN, EtOH and METF. 
To accomplish this, and as described in Manuscript C, we first 
characterized folic acid uptake by using 3H-FA. Uptake of 3H-FA was found to 
be markedly acidic pH-stimulated, suggesting that it involves the high-affinity 
folate: H+ symporter PCFT [145]. Accordingly, Keating et al. reported that FA 
uptake by human term CTBs obtained from normal pregnancies (NTB cells) is 
pH-dependent, operating optimally at acidic pH (5.0–5.5), and shows different 
transport characteristics at acidic (5.5) and physiological (7.5) pH [53]. This 
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point to a major putative role of PCFT as a placental FA transporter. We here 
hypothesize that, as the experiments were performed at acidic (5.5) pH, FA 
uptake might occur directly from the cell membrane, without further need of 
internalization of PCFT into an endosome (Fig. 15). Next, we verified that 
short-term exposure to XN inhibited 3H-FA uptake in a concentration-
dependent manner (Fig. 15.). However, long-term exposure to XN (24 h) did 
not consistently affect 3H-FA uptake.  
In the second part of Chapter III, and as described in Manuscript B, we 
characterized the long-term effect of the drug the abuse EtOH and the 
therapeutic drug METF upon folic acid uptake by HTR-8/SVneo cells. We 
observed that long-term exposure (24 h) to both EtOH (1-100 µM) and METF 
(0.01-1 mM) concentration-dependently inhibited 3H-FA uptake. The 
inhibitory effect of EtOH upon 3H-FA uptake is not surprising, as consumption 
of EtOH has been described to lead to FA deficiency and to both being 
associated with alcoholic liver disease (ALD)[146]. Also, the inhibitory effect 
of METF upon 3H-FA uptake is not unexpected, as several studies show that 
patients treated with METF are at risk of FA and vitamin B12 deficiency [147]. 
Furthermore, the inhibitory effect of long-term exposure to EtOH (100 μM) 
upon 3H-FA uptake was completely abolished by RAPA and reduced by 
SP600125 and by LY294002, indicating the involvement of mTOR, JNK and 
PI3K intracellular signaling pathways in this effect. Although we did not test 
for the putative involvement of Akt, we can hypothesize that this intracellular 
signaling pathway might also be involved, as it is classically described to 
belong to the PI3K/Akt/mTOR pathway. On the contrary, the effect of METF 
upon 3H-FA uptake was not affected by these inhibitors, excluding the 
involvement of these intracellular signaling pathways in this effect. These 
results are in good agreement with the results observed for the long-term 
effects of EtOH and METF upon 3H-DG uptake, described above. 
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Fig. 15. Effect of exposure to xanthohumol, ethanol and metformin upon folic 
acid uptake by HTR-8/SVneo cells. 
Inhibitory effect of XN, EtOH and METF upon 3H-FA uptake mediated by PCFT. 
EtOH inhibits mTOR, JNK and PI3K intracellular signaling pathways, which seems to 
be involved in the 3H-FA uptake mediated by PCFT. Akt is classically described as an 
intracellular signaling pathway downstream PI3K and upstream mTOR, thus we 
hypothesize that Akt might be also involved in the EtOH effect upon 3H-FA uptake 
mediated by PCFT. Akt: protein kinase B; EtOH: ethanol; EVT: extravillous 
trophoblasts; FA: folic acid; H+: proton; METF: metformin; mTOR: mammalian target 
of rapamycin; PCFT: proton-coupled folate transporter; PI3K: phosphatidylinositol-
4,5-bisphosphate 3-kinase; PM: plasma membrane. 
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CHAPTER IV – Modulation of L-MET transport in a human first-trimester 
EVTs cell line (HTR-8/SVneo cells) 
 
Due to the above-mentioned inhibitory effect of XN upon GLU and ARA 
uptake, we also decided to investigate modulation of the uptake of the neutral 
amino acid L-Met by short- and long-term exposure to XN, and these results 
are presented in Chapter IV. To accomplish this, and as described in 
Manuscript C, 14C-L-MET was used. Uptake of 14C-L-MET by HTR-8/SVneo 
cells was shown to be time-dependent. A short-term exposure (26 min) of the 
cells to XN (1-500 µM) reduced 14C-L-MET in a concentration-dependent 
manner. In contrast, a longer exposure (24h) of the cells to XN (0.03-5 µM) did 
not alter 14C-L-MET uptake. Considering this, we did not proceed to further 
characterize the effect of XN upon the uptake of L-Met by HTR-8/SVneo cells. 
 
 
 
CHAPTER V – Modulation of placentation-related processes in a human 
first-trimester EVTs cell line (HTR-8/SVneo cells) 
 
In the last part of this work (Chapter V), we studied modulation of 
placentation-related processes such as cell viability, proliferation, culture 
growth, migration and apoptosis index by xenobiotics other than the above 
described (ie., XN, EtOH and METF). 
We describe in Manuscript D, the effect of xenobiotics exposure upon 
placentation-related processes of first-trimester EVTs, and further unravel the 
putative involvement of the intracellular signaling pathways mTOR, cJNK and 
PI3K upon these xenobiotics effects. The compounds tested included the drugs 
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of abuse AMPH, MDMA, NICO, COCA, EtOH and its metabolite ACA, the 
methylxanthines CAF and TEO, and the therapeutic drugs FLUOX and METF. 
The results obtained in this study with AMPH, MDMA, COCA and NICO 
reinforce the idea of the harmfulness of all these drugs of abuse, with the 
exception of NICO, to placental function and fetal health. Indeed, AMPH and 
MDMA presented an antiproliferative and cytotoxic effect; MDMA was also 
shown to have an antimigratory effect in HTR-8/SVneo cells. In contrast, COCA 
presented a proproliferative and cytoprotective effect. However, COCA also 
increased the cell apoptosis index. Usually, increased cell apoptosis is 
associated with reduced cell viability. Hence, we hypothesize that this increase 
in cell viability, proliferation and culture growth could be in response to the 
increased cell apoptosis index, thus, an increased cell turnover, in an attempt 
to maintain the cell population. It is worth of note that in our study, cell 
viability was determined by LDH assay, by measuring the release of the 
enzyme lactate dehydrogenase. Interestingly, a key signature for necrotic cells 
is the permeabilization of plasma membrane [148], hence the cell viability 
quantified in our study by LDH assay corresponds to the amount of cell 
necrosis. As well reviewed by Sten Orrenius et al. 2010 [149], apoptosis and 
necrosis are viewed as separate modes of cell death with distinct 
morphological characteristics, are controlled by complex signaling networks, 
comprising ‘‘switches’’ responsible for cross talk between them. Depending on 
the type of the cellular injury and on the severity (i.e. concentration) of the 
toxic agent under study, cell death in the form of either apoptosis or necrosis 
can be triggered. Most often, exposure to low doses results in apoptosis, 
whereas higher levels of the same toxic agent might cause necrosis [149, 150]. 
Indeed, several studies points to the fact that at lower doses of a toxic agent 
activation of apoptosis was observed, without observed alterations upon 
necrosis. In primary cultures of mouse proximal tubular cells, low 
concentrations of cisplatin (8 µM) led to apoptosis whilst only with higher 
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cisplatin concentrations (800 µM) cell necrosis was observed [151]. In LLC-
PK1 renal proximal tubular cell line, low dose (4.2 nM) cyclosporine A induced 
apoptosis (quantified by TUNEL assay) whereas high dose (21 mM or greater) 
of cyclosporine A induced necrosis (quantified by LDH assay)[152]. Also, in 
the UVB-exposed HaCaT cells (human keratinocytes), extract of laver 
(Porphyra yezoensis) significantly increased the net viability and also the 
apoptotic cell [153]. As such, we can speculate that in our study, the COCA 
concentration was high enough to induce cell apoptosis but not as high to 
trigger cell necrosis, thus the increased cell viability (or reduced cell necrosis) 
observed. Another interesting hypothesis to the observation of increased cell 
apoptosis is the fact that classically, alterations in Ca2+ homeostasis can trigger 
or modulate an apoptotic response [149]. Interestingly enough, COCA is 
classically described to alter Ca2+ influx and storage in several brain cell lines. 
For instance, in rat brain microvascular endothelial cells (RBMVEC), COCA 
dramatically inhibits store-operated Ca2+ entry, a Ca2+ influx mechanism 
promoted by depletion of intracellular Ca2+ stores [154]. Therefore, we can 
theorize that in our study, COCA may affect Ca2+ homeostasis, thus enhancing 
an apoptotic response.  
Overall, these results reinforce the idea of the harmfulness of drugs of 
abuse to placental function and fetal health, as these drugs are known to freely 
cross the placenta barrier, being associated with increased maternal and (or) 
fetal morbidity and mortality, higher risks of low birth weight, preterm 
delivery and teratogenesis [43, 45]. 
Interestingly enough, TEO was shown to present a cytotoxic and 
antimigratory effect, while CAF presented a stimulatory effect upon the 
placentation-promoting parameters tested. Regarding the therapeutic drugs, 
long-term FLUOX presented an antiproliferative and cytotoxic effect in HTR-
8/SVneo cells, although it was devoid of effect on cell migration. This is 
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consistent with several studies that correlate the use of antidepressant during 
pregnancy with FGR and premature delivery [62, 155-157].  
In summary, our results show a detrimental effect of the drugs of 
abuse AMPH, MDMA, and COCA, of the methylxanthine TEO and of the 
therapeutic drugs FLUOX in placentation-related processes of EVTs. 
Interestingly enough, CAF seems to favor HTR-8/SVneo cells placentation 
capacity. Nevertheless we understand that there is still some controversy 
concerning the risks associated with the maternal use of CAF during 
pregnancy (e.g. spontaneous abortion and fetal growth restriction), the FDA 
recommends that pregnant women should avoid the ingestion of CAF.
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The final conclusions of this study are listed below.  
1) GLU transport to HTR-8/SVneo cells involves GLUT, most probably GLUT1, 
and is affected by short-term exposure to different xenobiotics, including XN; 
long-term exposure to XN impairs placentation-related processes in a GLU-
dependent manner. 
2) GLU transport to HTR-8/SVneo cells is inhibited by long-term exposure to 
both EtOH and METF. 
3) ARA transport to HTR-8/SVneo cells involves ACSL1 and is affected by XN, 
which impairs placentation-related processes in an ARA-dependent manner. 
4) FA uptake by HTR-8/SVneo cells involves PCFT, and is affected by long-
term exposure to EtOH and METF. 
5) Long-term exposure to EtOH and METF impairs placentation-related 
processes. 
6) Long-term exposure to XN impairs placentation-related processes and thus 
induces an insufficient phenotype in HTR-8/SVneo cells, which may 
contribute to the development of an experimental insufficient cellular model 
of EVTs. 
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Future perspectives 
We believe that this work contributed for a better knowledge on the 
impact of xenobiotics upon the placental transport of nutrients and placental 
development during first trimester of pregnancy. However, it also showed that 
new aspects should be investigated in more detail, namely:  
1) the modulation of placental transport of GLU upon HTR-8/SVneo cells by 
xenobiotics, including XN, and the putative involvement of GLUT3, as we did 
not observe statistically significant alterations upon GLUT1 gene expression 
and protein levels after XN exposure. 
2) the involvement of intracellular signaling pathways on the XN effect upon 
placentation-related properties. 
3) whether the observed effects of EtOH and METF upon placentation-related 
properties are dependent on GLU or FA. 
4) the impact of XN upon placentation-related properties, placental and fetal 
development in vivo. 
 
 
 
 
 
 
 
 
- 176 - 
 
- 177 - 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
- 178 - 
 
 
- 179 - 
 
REFERENCES 
 
1. Fowden, A.L., et al., The placenta and intrauterine programming. J 
Neuroendocrinol, 2008. 20(4): p. 439-50. 
2. Sandovici, I., et al., Placental adaptations to the maternal-fetal environment: 
implications for fetal growth and developmental programming. Reprod Biomed 
Online, 2012. 25(1): p. 68-89. 
3. Fowden, A.L., et al., Placental efficiency and adaptation: endocrine regulation. J 
Physiol, 2009. 587(Pt 14): p. 3459-72. 
4. Costa, M.A., The endocrine function of human placenta: an overview. Reprod 
Biomed Online, 2016. 32(1): p. 14-43. 
5. James, J.L., A.M. Carter, and L.W. Chamley, Human placentation from nidation to 
5 weeks of gestation. Part I: What do we know about formative placental 
development following implantation? Placenta, 2012. 33(5): p. 327-34. 
6. Ji, L., et al., Placental trophoblast cell differentiation: physiological regulation and 
pathological relevance to preeclampsia. Mol Aspects Med, 2013. 34(5): p. 981-
1023. 
7. Graham, C.H., et al., Establishment and characterization of first trimester human 
trophoblast cells with extended lifespan. Exp Cell Res, 1993. 206(2): p. 204-11. 
8. Abou-Kheir, W., et al., HTR-8/SVneo cell line contains a mixed population of cells. 
Placenta, 2017. 50: p. 1-7. 
9. Knofler, M., Critical growth factors and signalling pathways controlling human 
trophoblast invasion. Int J Dev Biol, 2010. 54(2-3): p. 269-80. 
10. Aplin, J.D., et al., Trophoblast differentiation: progenitor cells, fusion and migration -
- a workshop report. Placenta, 2006. 27 Suppl A: p. S141-3. 
11. Baumann, M.U., S. Deborde, and N.P. Illsley, Placental glucose transfer and fetal 
growth. Endocrine, 2002. 19(1): p. 13-22. 
12. Avagliano, L., C. Garo, and A.M. Marconi, Placental amino acids transport in 
intrauterine growth restriction. J Pregnancy, 2012. 2012: p. 972562. 
13. Pantham, P., et al., Down-Regulation of Placental Transport of Amino Acids 
Precedes the Development of Intrauterine Growth Restriction in Maternal Nutrient 
Restricted Baboons. Biol Reprod, 2016. 95(5): p. 98. 
14. Keating, E., et al., Comparison of the transport characteristics of bioactive 
substances in IUGR and normal placentas. Pediatr Res, 2009. 66(5): p. 495-500. 
- 180 - 
 
15. Regnault, T.R., et al., Fetoplacental transport and utilization of amino acids in 
IUGR--a review. Placenta, 2005. 26 Suppl A: p. S52-62. 
16. Battaglia, F.C., Clinical studies linking fetal velocimetry, blood flow and placental 
transport in pregnancies complicated by intrauterine growth retardation (IUGR). 
Trans Am Clin Climatol Assoc, 2003. 114: p. 305-13. 
17. Jansson, T., L. Myatt, and T.L. Powell, The role of trophoblast nutrient and ion 
transporters in the development of pregnancy complications and adult disease. 
Curr Vasc Pharmacol, 2009. 7(4): p. 521-33. 
18. Magnusson, A.L., et al., Glucose metabolism in the human preterm and term 
placenta of IUGR fetuses. Placenta, 2004. 25(4): p. 337-46. 
19. Leonce, J., et al., Glucose production in the human placenta. Placenta, 2006. 27 
Suppl A: p. S103-8. 
20. Carter, A.M., Evolution of placental function in mammals: the molecular basis of 
gas and nutrient transfer, hormone secretion, and immune responses. Physiol Rev, 
2012. 92(4): p. 1543-76. 
21. Illsley, N.P., Glucose transporters in the human placenta. Placenta, 2000. 21(1): p. 
14-22. 
22. Stanirowski, P.J., et al., Expression of Glucose Transporter Proteins in Human 
Diabetic Placenta. Can J Diabetes, 2017. 
23. Larance, M., G. Ramm, and D.E. James, The GLUT4 code. Mol Endocrinol, 2008. 
22(2): p. 226-33. 
24. Xing, A.Y., et al., Unexpected expression of glucose transporter 4 in villous stromal 
cells of human placenta. J Clin Endocrinol Metab, 1998. 83(11): p. 4097-101. 
25. Boileau, P., et al., Dissociation between insulin-mediated signaling pathways and 
biological effects in placental cells: role of protein kinase B and MAPK 
phosphorylation. Endocrinology, 2001. 142(9): p. 3974-9. 
26. Gude, N.M., et al., GLUT12 expression in human placenta in first trimester and 
term. Placenta, 2003. 24(5): p. 566-70. 
27. Brown, K., et al., Glucose transporter 3 (GLUT3) protein expression in human 
placenta across gestation. Placenta, 2011. 32(12): p. 1041-9. 
28. Dutta-Roy, A.K., Transport mechanisms for long-chain polyunsaturated fatty acids 
in the human placenta. Am J Clin Nutr, 2000. 71(1 Suppl): p. 315S-22S. 
29. Innis, S.M., Fatty acids and early human development. Early Hum Dev, 2007. 
83(12): p. 761-6. 
30. Cunningham, P. and L. McDermott, Long chain PUFA transport in human term 
placenta. J Nutr, 2009. 139(4): p. 636-9. 
- 181 - 
 
31. Innis, S.M., Essential fatty acid transfer and fetal development. Placenta, 2005. 26 
Suppl A: p. S70-5. 
32. Larque, E., et al., Placental transfer of fatty acids and fetal implications. Am J Clin 
Nutr, 2011. 94(6 Suppl): p. 1908S-1913S. 
33. Greenberg, J.A., S.J. Bell, and W.V. Ausdal, Omega-3 Fatty Acid supplementation 
during pregnancy. Rev Obstet Gynecol, 2008. 1(4): p. 162-9. 
34. Koletzko, B., et al., The roles of long-chain polyunsaturated fatty acids in 
pregnancy, lactation and infancy: review of current knowledge and consensus 
recommendations. J Perinat Med, 2008. 36(1): p. 5-14. 
35. Hanebutt, F.L., et al., Long-chain polyunsaturated fatty acid (LC-PUFA) transfer 
across the placenta. Clin Nutr, 2008. 27(5): p. 685-93. 
36. Lager, S. and T.L. Powell, Regulation of nutrient transport across the placenta. J 
Pregnancy, 2012. 2012: p. 179827. 
37. Araujo, J.R., et al., A parallel increase in placental oxidative stress and antioxidant 
defenses occurs in pre-gestational type 1 but not gestational diabetes. Placenta, 
2013. 34(11): p. 1095-8. 
38. Duttaroy, A.K., Transport of fatty acids across the human placenta: a review. Prog 
Lipid Res, 2009. 48(1): p. 52-61. 
39. Tobin, K.A., et al., Long-chain polyunsaturated fatty acid transport across human 
placental choriocarcinoma (BeWo) cells. Placenta, 2009. 30(1): p. 41-7. 
40. Basak, S., M.K. Das, and A.K. Duttaroy, Fatty acid-induced angiogenesis in first 
trimester placental trophoblast cells: possible roles of cellular fatty acid-binding 
proteins. Life Sci, 2013. 93(21): p. 755-62. 
41. Soupene, E. and F.A. Kuypers, Mammalian long-chain acyl-CoA synthetases. Exp 
Biol Med (Maywood), 2008. 233(5): p. 507-21. 
42. Lucock, M., Folic acid: nutritional biochemistry, molecular biology, and role in 
disease processes. Mol Genet Metab, 2000. 71(1-2): p. 121-38. 
43. Pitkin, R.M., Folate and neural tube defects. Am J Clin Nutr, 2007. 85(1): p. 285S-
288S. 
44. Gong, R., et al., Effects of folic acid supplementation during different pregnancy 
periods and relationship with the other primary prevention measures to neural tube 
defects. J Matern Fetal Neonatal Med, 2016. 29(23): p. 3894-901. 
45. Prevention of neural tube defects: results of the Medical Research Council Vitamin 
Study. MRC Vitamin Study Research Group. Lancet, 1991. 338(8760): p. 131-7. 
46. Ganapathy, V., S.B. Smith, and P.D. Prasad, SLC19: the folate/thiamine 
transporter family. Pflugers Arch, 2004. 447(5): p. 641-6. 
- 182 - 
 
47. Prasad, P.D., et al., Molecular cloning of the human placental folate transporter. 
Biochem Biophys Res Commun, 1995. 206(2): p. 681-7. 
48. Whetstine, J.R., R.M. Flatley, and L.H. Matherly, The human reduced folate carrier 
gene is ubiquitously and differentially expressed in normal human tissues: 
identification of seven non-coding exons and characterization of a novel promoter. 
Biochem J, 2002. 367(Pt 3): p. 629-40. 
49. Zhao, R., et al., Mechanisms of membrane transport of folates into cells and across 
epithelia. Annu Rev Nutr, 2011. 31: p. 177-201. 
50. Kamen, B.A. and A.K. Smith, A review of folate receptor alpha cycling and 5-
methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv 
Drug Deliv Rev, 2004. 56(8): p. 1085-97. 
51. Matherly, L.H. and D.I. Goldman, Membrane transport of folates. Vitam Horm, 
2003. 66: p. 403-56. 
52. Zhao, R. and I.D. Goldman, The molecular identity and characterization of a 
Proton-coupled Folate Transporter--PCFT; biological ramifications and impact on 
the activity of pemetrexed. Cancer Metastasis Rev, 2007. 26(1): p. 129-39. 
53. Keating, E., et al., Folic acid uptake by the human syncytiotrophoblast: interference 
by pharmacotherapy, drugs of abuse and pathological conditions. Reprod Toxicol, 
2009. 28(4): p. 511-20. 
54. Solanky, N., et al., Expression of folate transporters in human placenta and 
implications for homocysteine metabolism. Placenta, 2010. 31(2): p. 134-43. 
55. Keating, E., et al., Acute and chronic effects of some dietary bioactive compounds 
on folic acid uptake and on the expression of folic acid transporters by the human 
trophoblast cell line BeWo. J Nutr Biochem, 2008. 19(2): p. 91-100. 
56. Cleal, J.K. and R.M. Lewis, The mechanisms and regulation of placental amino 
acid transport to the human foetus. J Neuroendocrinol, 2008. 20(4): p. 419-26. 
57. Kalhan, S.C. and S.E. Marczewski, Methionine, homocysteine, one carbon 
metabolism and fetal growth. Rev Endocr Metab Disord, 2012. 13(2): p. 109-19. 
58. Desforges, M. and C.P. Sibley, Placental nutrient supply and fetal growth. Int J Dev 
Biol, 2010. 54(2-3): p. 377-90. 
59. Jansson, T., Amino acid transporters in the human placenta. Pediatr Res, 2001. 
49(2): p. 141-7. 
60. Ayuk, P.T., et al., Development and polarization of cationic amino acid transporters 
and regulators in the human placenta. Am J Physiol Cell Physiol, 2000. 278(6): p. 
C1162-71. 
61. Tsitsiou, E., et al., Homocysteine transport by systems L, A and y+L across the 
microvillous plasma membrane of human placenta. J Physiol, 2009. 587(Pt 16): p. 
4001-13. 
- 183 - 
 
62. Ganapathy, V., Drugs of abuse and human placenta. Life Sci, 2011. 88(21-22): p. 
926-30. 
63. Aden, U., Methylxanthines during pregnancy and early postnatal life. Handb Exp 
Pharmacol, 2011(200): p. 373-89. 
64. Grosso, L.M. and M.B. Bracken, Caffeine metabolism, genetics, and perinatal 
outcomes: a review of exposure assessment considerations during pregnancy. Ann 
Epidemiol, 2005. 15(6): p. 460-6. 
65. Belik, J., Fetal and neonatal effects of maternal drug treatment for depression. 
Semin Perinatol, 2008. 32(5): p. 350-4. 
66. Muzik, M. and S.E. Hamilton, Use of Antidepressants During Pregnancy?: What to 
Consider when Weighing Treatment with Antidepressants Against Untreated 
Depression. Matern Child Health J, 2016. 20(11): p. 2268-2279. 
67. Rowan, J.A., et al., Metformin in gestational diabetes: the offspring follow-up (MiG 
TOFU): body composition at 2 years of age. Diabetes Care, 2011. 34(10): p. 2279-
84. 
68. Kirpichnikov, D., S.I. McFarlane, and J.R. Sowers, Metformin: an update. Ann 
Intern Med, 2002. 137(1): p. 25-33. 
69. Charles, B., et al., Population pharmacokinetics of metformin in late pregnancy. 
Ther Drug Monit, 2006. 28(1): p. 67-72. 
70. Inzucchi, S.E., et al., Management of hyperglycaemia in type 2 diabetes: a patient-
centered approach. Position statement of the American Diabetes Association 
(ADA) and the European Association for the Study of Diabetes (EASD). 
Diabetologia, 2012. 55(6): p. 1577-96. 
71. Qaseem, A., et al., Oral pharmacologic treatment of type 2 diabetes mellitus: a 
clinical practice guideline from the American College of Physicians. Ann Intern 
Med, 2012. 156(3): p. 218-31. 
72. Ainuddin, J., et al., Metformin versus insulin treatment in gestational diabetes in 
pregnancy in a developing country: a randomized control trial. Diabetes Res Clin 
Pract, 2015. 107(2): p. 290-9. 
73. Rowan, J.A., et al., Metformin versus insulin for the treatment of gestational 
diabetes. N Engl J Med, 2008. 358(19): p. 2003-15. 
74. Vanky, E., et al., Placental passage of metformin in women with polycystic ovary 
syndrome. Fertil Steril, 2005. 83(5): p. 1575-8. 
75. Grekin, E.R., et al., Drug use during pregnancy: validating the Drug Abuse 
Screening Test against physiological measures. Psychol Addict Behav, 2010. 
24(4): p. 719-23. 
76. Halsted, C.H., et al., Metabolic interactions of alcohol and folate. J Nutr, 2002. 
132(8 Suppl): p. 2367S-2372S. 
- 184 - 
 
77. Schuchat, A., The CDC's Recommendations to Help Prevent Fetal Alcohol 
Spectrum Disorders. Am Fam Physician, 2017. 95(1): p. 6-7. 
78. Sundelin-Wahlsten, V., G. Hallberg, and A. Helander, Higher alcohol consumption 
in early pregnancy or low-to-moderate drinking during pregnancy may affect 
children's behaviour and development at one year and six months. Acta Paediatr, 
2017. 106(3): p. 446-453. 
79. Krulewitch, C.J., Alcohol consumption during pregnancy. Annu Rev Nurs Res, 
2005. 23: p. 101-34. 
80. Riveros-Rosas, H., A. Julian-Sanchez, and E. Pina, Enzymology of ethanol and 
acetaldehyde metabolism in mammals. Arch Med Res, 1997. 28(4): p. 453-71. 
81. Antoshechkin, A.G., On intracellular formation of ethanol and its possible role in 
energy metabolism. Alcohol Alcohol, 2001. 36(6): p. 608. 
82. Abel, E.L., Prenatal effects of alcohol. Drug Alcohol Depend, 1984. 14(1): p. 1-10. 
83. Goodlett, C.R., K.H. Horn, and F.C. Zhou, Alcohol teratogenesis: mechanisms of 
damage and strategies for intervention. Exp Biol Med (Maywood), 2005. 230(6): p. 
394-406. 
84. O'Callaghan, F.V., et al., Maternal smoking during pregnancy predicts nicotine 
disorder (dependence or withdrawal) in young adults - a birth cohort study. Aust N 
Z J Public Health, 2009. 33(4): p. 371-7. 
85. Andersen, M.R., et al., Smoking cessation early in pregnancy and birth weight, 
length, head circumference, and endothelial nitric oxide synthase activity in 
umbilical and chorionic vessels: an observational study of healthy singleton 
pregnancies. Circulation, 2009. 119(6): p. 857-64. 
86. Taghavi, T., et al., Longitudinal Influence of Pregnancy on Nicotine Metabolic 
Pathways. J Pharmacol Exp Ther, 2017. 
87. Lall, R.K., et al., Dietary polyphenols in prevention and treatment of prostate 
cancer. Int J Mol Sci, 2015. 16(2): p. 3350-76. 
88. Teixeira, J., et al., Dietary Polyphenols and Mitochondrial Function: Role in Health 
and Disease. Curr Med Chem, 2017. 
89. Mocanu, M.M., P. Nagy, and J. Szollosi, Chemoprevention of Breast Cancer by 
Dietary Polyphenols. Molecules, 2015. 20(12): p. 22578-620. 
90. Morand, C. and H. Sies, Special Issue: "Polyphenols and health". Arch Biochem 
Biophys, 2016. 599: p. 1-2. 
91. Visioli, F., et al., Polyphenols and human health: a prospectus. Crit Rev Food Sci 
Nutr, 2011. 51(6): p. 524-46. 
92. Wang, S., et al., Novel insights of dietary polyphenols and obesity. J Nutr Biochem, 
2014. 25(1): p. 1-18. 
- 185 - 
 
93. Li, Y., et al., Quercetin, Inflammation and Immunity. Nutrients, 2016. 8(3): p. 167. 
94. Stevens, J.F. and J.E. Page, Xanthohumol and related prenylflavonoids from hops 
and beer: to your good health! Phytochemistry, 2004. 65(10): p. 1317-30. 
95. Xiao, J., Dietary flavonoid aglycones and their glycosides: Which show better 
biological significance? Crit Rev Food Sci Nutr, 2017. 57(9): p. 1874-1905. 
96. Safranow, K. and Z. Machoy, Methylated purines in urinary stones. Clin Chem, 
2005. 51(8): p. 1493-8. 
97. Heckman, M.A., J. Weil, and E. Gonzalez de Mejia, Caffeine (1, 3, 7-
trimethylxanthine) in foods: a comprehensive review on consumption, functionality, 
safety, and regulatory matters. J Food Sci, 2010. 75(3): p. R77-87. 
98. Bracken, M.B., et al., Association of maternal caffeine consumption with 
decrements in fetal growth. Am J Epidemiol, 2003. 157(5): p. 456-66. 
99. Oesterheld, J.R., A review of developmental aspects of cytochrome P450. J Child 
Adolesc Psychopharmacol, 1998. 8(3): p. 161-74. 
100. Jarosz, M., R. Wierzejska, and M. Siuba, Maternal caffeine intake and its effect on 
pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol, 2012. 160(2): p. 156-60. 
101. Hey, E., Coffee and pregnancy. BMJ, 2007. 334(7590): p. 377. 
102. van der Hoeven, T., et al., Antenatal coffee and tea consumption and the effect on 
birth outcome and hypertensive pregnancy disorders. PLoS One, 2017. 12(5): p. 
e0177619. 
103. Dimasuay, K.G., et al., Placental Responses to Changes in the Maternal 
Environment Determine Fetal Growth. Front Physiol, 2016. 7: p. 12. 
104. Jansson, T., I.L. Aye, and D.C. Goberdhan, The emerging role of mTORC1 
signaling in placental nutrient-sensing. Placenta, 2012. 33 Suppl 2: p. e23-9. 
105. Rosario, F.J., et al., Maternal folate deficiency causes inhibition of mTOR signaling, 
down-regulation of placental amino acid transporters and fetal growth restriction in 
mice. Sci Rep, 2017. 7(1): p. 3982. 
106. Burton, G.J., A.L. Fowden, and K.L. Thornburg, Placental Origins of Chronic 
Disease. Physiol Rev, 2016. 96(4): p. 1509-65. 
107. Roos, S., T.L. Powell, and T. Jansson, Placental mTOR links maternal nutrient 
availability to fetal growth. Biochem Soc Trans, 2009. 37(Pt 1): p. 295-8. 
108. Roos, S., et al., Regulation of placental amino acid transporter activity by 
mammalian target of rapamycin. Am J Physiol Cell Physiol, 2009. 296(1): p. C142-
50. 
109. Rosario, F.J., T.L. Powell, and T. Jansson, mTOR folate sensing links folate 
availability to trophoblast cell function. J Physiol, 2017. 595(13): p. 4189-4206. 
- 186 - 
 
110. Yang, Q. and K.L. Guan, Expanding mTOR signaling. Cell Res, 2007. 17(8): p. 
666-81. 
111. Ma, X.M. and J. Blenis, Molecular mechanisms of mTOR-mediated translational 
control. Nat Rev Mol Cell Biol, 2009. 10(5): p. 307-18. 
112. Wullschleger, S., R. Loewith, and M.N. Hall, TOR signaling in growth and 
metabolism. Cell, 2006. 124(3): p. 471-84. 
113. Yung, H.W., D.S. Charnock-Jones, and G.J. Burton, Regulation of AKT 
phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates 
substrate specificity in a severity dependent manner. PLoS One, 2011. 6(3): p. 
e17894. 
114. Inoki, K., T. Zhu, and K.L. Guan, TSC2 mediates cellular energy response to 
control cell growth and survival. Cell, 2003. 115(5): p. 577-90. 
115. Roos, S., et al., Mammalian target of rapamycin in the human placenta regulates 
leucine transport and is down-regulated in restricted fetal growth. J Physiol, 2007. 
582(Pt 1): p. 449-59. 
116. Rosario, F.J., T.L. Powell, and T. Jansson, Mechanistic target of rapamycin 
(mTOR) regulates trophoblast folate uptake by modulating the cell surface 
expression of FR-alpha and the RFC. Sci Rep, 2016. 6: p. 31705. 
117. Sferruzzi-Perri, A.N., et al., Placental-specific Igf2 deficiency alters developmental 
adaptations to undernutrition in mice. Endocrinology, 2011. 152(8): p. 3202-12. 
118. Gaccioli, F., et al., Maternal overweight induced by a diet with high content of 
saturated fat activates placental mTOR and eIF2alpha signaling and increases fetal 
growth in rats. Biol Reprod, 2013. 89(4): p. 96. 
119. Lager, S., et al., Diet-induced obesity in mice reduces placental efficiency and 
inhibits placental mTOR signaling. Physiol Rep, 2014. 2(2): p. e00242. 
120. Zhu, M.J., et al., Down-regulation of growth signaling pathways linked to a reduced 
cotyledonary vascularity in placentomes of over-nourished, obese pregnant ewes. 
Placenta, 2009. 30(5): p. 405-10. 
121. Martin, P.M. and A.E. Sutherland, Exogenous amino acids regulate trophectoderm 
differentiation in the mouse blastocyst through an mTOR-dependent pathway. Dev 
Biol, 2001. 240(1): p. 182-93. 
122. Gangloff, Y.G., et al., Disruption of the mouse mTOR gene leads to early 
postimplantation lethality and prohibits embryonic stem cell development. Mol Cell 
Biol, 2004. 24(21): p. 9508-16. 
123. Yang, Z.Z., et al., Protein kinase B alpha/Akt1 regulates placental development and 
fetal growth. J Biol Chem, 2003. 278(34): p. 32124-31. 
124. Wright, E.M., M.G. Martin, and E. Turk, Intestinal absorption in health and disease--
sugars. Best Pract Res Clin Gastroenterol, 2003. 17(6): p. 943-56. 
- 187 - 
 
125. Dwarakanath, B.S., Cytotoxicity, radiosensitization, and chemosensitization of 
tumor cells by 2-deoxy-D-glucose in vitro. J Cancer Res Ther, 2009. 5 Suppl 1: p. 
S27-31. 
126. Belkacemi, L., et al., Inhibition of human trophoblast invasiveness by high glucose 
concentrations. J Clin Endocrinol Metab, 2005. 90(8): p. 4846-51. 
127. Ehrenkranz, J.R., et al., Phlorizin: a review. Diabetes Metab Res Rev, 2005. 21(1): 
p. 31-8. 
128. Goncalves, P., et al., Lack of a significant effect of cannabinoids upon the uptake of 
2-deoxy-D-glucose by Caco-2 cells. Pharmacology, 2008. 82(1): p. 30-7. 
129. Moreira, L., et al., Quercetin and epigallocatechin gallate inhibit glucose uptake and 
metabolism by breast cancer cells by an estrogen receptor-independent 
mechanism. Exp Cell Res, 2013. 319(12): p. 1784-95. 
130. March, H.N. and D.J. Winton, mTOR regulation by JNK: rescuing the starving 
intestinal cancer cell? Gastroenterology, 2011. 140(5): p. 1387-91. 
131. Deeb, D., et al., Growth inhibitory and apoptosis-inducing effects of xanthohumol, a 
prenylated chalone present in hops, in human prostate cancer cells. Anticancer 
Res, 2010. 30(9): p. 3333-9. 
132. Fisher, S.J., The placental problem: linking abnormal cytotrophoblast differentiation 
to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol, 2004. 2: p. 53. 
133. Neri, M., et al., Drugs of abuse in pregnancy, poor neonatal development, and 
future neurodegeneration. Is oxidative stress the culprit? Curr Pharm Des, 2015. 
21(11): p. 1358-68. 
134. Wright, A. and J. Walker, Drugs of abuse in pregnancy. Best Pract Res Clin Obstet 
Gynaecol, 2001. 15(6): p. 987-98. 
135. Pryor, J., et al., Pregnancy Intention and Maternal Alcohol Consumption. Obstet 
Gynecol, 2017. 129(4): p. 727-733. 
136. Araujo, J.R., P. Goncalves, and F. Martel, Modulation of glucose uptake in a 
human choriocarcinoma cell line (BeWo) by dietary bioactive compounds and 
drugs of abuse. J Biochem, 2008. 144(2): p. 177-86. 
137. Grisouard, J., et al., Mechanisms of metformin action on glucose transport and 
metabolism in human adipocytes. Biochem Pharmacol, 2010. 80(11): p. 1736-45. 
138. Zhao, Y., et al., Metformin is associated with reduced cell proliferation in human 
endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. Gynecol Endocrinol, 
2018. 34(5): p. 428-432. 
139. Wolff, G.S., et al., Epidermal growth factor-like growth factors prevent apoptosis of 
alcohol-exposed human placental cytotrophoblast cells. Biol Reprod, 2007. 77(1): 
p. 53-60. 
- 188 - 
 
140. Bolnick, J.M., et al., Apoptosis of alcohol-exposed human placental cytotrophoblast 
cells is downstream of intracellular calcium signaling. Alcohol Clin Exp Res, 2014. 
38(6): p. 1646-53. 
141. Bonen, A., et al., Is membrane transport of FFA mediated by lipid, protein, or both? 
Mechanisms and regulation of protein-mediated cellular fatty acid uptake: 
molecular, biochemical, and physiological evidence. Physiology (Bethesda), 2007. 
22: p. 15-29. 
142. Doege, H. and A. Stahl, Protein-mediated fatty acid uptake: novel insights from in 
vivo models. Physiology (Bethesda), 2006. 21: p. 259-68. 
143. Correia-Branco, A., et al., Xanthohumol impairs glucose uptake by a human first-
trimester extravillous trophoblast cell line (HTR-8/SVneo cells) and impacts the 
process of placentation. Mol Hum Reprod, 2015. 21(10): p. 803-15. 
144. Kliman, H.J., et al., Purification, characterization, and in vitro differentiation of 
cytotrophoblasts from human term placentae. Endocrinology, 1986. 118(4): p. 
1567-82. 
145. Qiu, A., et al., Identification of an intestinal folate transporter and the molecular 
basis for hereditary folate malabsorption. Cell, 2006. 127(5): p. 917-28. 
146. Medici, V. and C.H. Halsted, Folate, alcohol, and liver disease. Mol Nutr Food Res, 
2013. 57(4): p. 596-606. 
147. Xu, L., et al., Adverse effect of metformin therapy on serum vitamin B12 and folate: 
short-term treatment causes disadvantages? Med Hypotheses, 2013. 81(2): p. 149-
51. 
148. Chan, F.K., K. Moriwaki, and M.J. De Rosa, Detection of necrosis by release of 
lactate dehydrogenase activity. Methods Mol Biol, 2013. 979: p. 65-70. 
149. Orrenius, S., P. Nicotera, and B. Zhivotovsky, Cell death mechanisms and their 
implications in toxicology. Toxicol Sci, 2011. 119(1): p. 3-19. 
150. Kerr, J.F., Neglected opportunities in apoptosis research. Trends Cell Biol, 1995. 
5(2): p. 55-7. 
151. Lieberthal, W., V. Triaca, and J. Levine, Mechanisms of death induced by cisplatin 
in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol, 1996. 
270(4 Pt 2): p. F700-8. 
152. Healy, E., et al., Apoptosis and necrosis: mechanisms of cell death induced by 
cyclosporine A in a renal proximal tubular cell line. Kidney Int, 1998. 54(6): p. 1955-
66. 
153. Kim, S., et al., Modulation of viability and apoptosis of UVB-exposed human 
keratinocyte HaCaT cells by aqueous methanol extract of laver (Porphyra 
yezoensis). J Photochem Photobiol B, 2014. 141: p. 301-7. 
- 189 - 
 
154. Brailoiu, G.C., et al., Cocaine inhibits store-operated Ca2+ entry in brain 
microvascular endothelial cells: critical role for sigma-1 receptors. Biochem J, 2016. 
473(1): p. 1-5. 
155. Kallen, B., The safety of antidepressant drugs during pregnancy. Expert Opin Drug 
Saf, 2007. 6(4): p. 357-70. 
156. Way, C.M., Safety of newer antidepressants in pregnancy. Pharmacotherapy, 
2007. 27(4): p. 546-52. 
157. Wisner, K.L., et al., Major depression and antidepressant treatment: impact on 
pregnancy and neonatal outcomes. Am J Psychiatry, 2009. 166(5): p. 557-66. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 190 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 191 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Home is now behind you, the world is ahead!” 
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